<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cells</journal-id>
<journal-id journal-id-type="iso-abbrev">Cells</journal-id>
<journal-id journal-id-type="publisher-id">cells</journal-id>
<journal-title-group>
<journal-title>Cells</journal-title>
</journal-title-group>
<issn pub-type="epub">2073-4409</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30875781</article-id>
<article-id pub-id-type="pmc">6468789</article-id>
<article-id pub-id-type="doi">10.3390/cells8030242</article-id>
<article-id pub-id-type="publisher-id">cells-08-00242</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Use of Pluripotent Stem Cell-Derived Organoids to Study Extracellular Matrix Development during Neural Degeneration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yan</surname>
<given-names>Yuanwei</given-names>
</name>
<xref ref-type="author-notes" rid="fn1-cells-08-00242">†</xref>
<xref ref-type="author-notes" rid="fn2-cells-08-00242">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bejoy</surname>
<given-names>Julie</given-names>
</name>
<xref ref-type="author-notes" rid="fn2-cells-08-00242">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marzano</surname>
<given-names>Mark</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="corresp" rid="c1-cells-08-00242">*</xref>
</contrib>
</contrib-group>
<aff id="af1-cells-08-00242">Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL 32310, USA; <email>yyan73@wisc.edu</email> (Y.Y.); <email>julie1.bejoy@famu.edu</email> (J.B.); <email>mcm12g@my.fsu.edu</email> (M.M.)</aff>
<author-notes>
<corresp id="c1-cells-08-00242"><label>*</label>Correspondence: <email>yli4@fsu.edu</email>; Tel.: +1-850-410-6320; Fax: +1-850-410-6150</corresp>
<fn id="fn1-cells-08-00242">
<label>†</label>
<p>Current address: Waisman Center, University of Wisconsin-Madison, Madison, WI 53706, USA.</p>
</fn>
<fn id="fn2-cells-08-00242">
<label>‡</label>
<p>These two authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2019</year>
</pub-date>
<volume>8</volume>
<issue>3</issue>
<elocation-id>242</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The mechanism that causes the Alzheimer’s disease (AD) pathologies, including amyloid plaque, neurofibrillary tangles, and neuron death, is not well understood due to the lack of robust study models for human brain. Three-dimensional organoid systems based on human pluripotent stem cells (hPSCs) have shown a promising potential to model neurodegenerative diseases, including AD. These systems, in combination with engineering tools, allow in vitro generation of brain-like tissues that recapitulate complex cell-cell and cell-extracellular matrix (ECM) interactions. Brain ECMs play important roles in neural differentiation, proliferation, neuronal network, and AD progression. In this contribution related to brain ECMs, recent advances in modeling AD pathology and progression based on hPSC-derived neural cells, tissues, and brain organoids were reviewed and summarized. In addition, the roles of ECMs in neural differentiation of hPSCs and the influences of heparan sulfate proteoglycans, chondroitin sulfate proteoglycans, and hyaluronic acid on the progression of neurodegeneration were discussed. The advantages that use stem cell-based organoids to study neural degeneration and to investigate the effects of ECM development on the disease progression were highlighted. The contents of this article are significant for understanding cell-matrix interactions in stem cell microenvironment for treating neural degeneration.</p>
</abstract>
<kwd-group>
<kwd>extracellular matrix</kwd>
<kwd>pluripotent stem cells</kwd>
<kwd>organoids</kwd>
<kwd>neural degeneration</kwd>
<kwd>three-dimensional</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-cells-08-00242" sec-type="intro">
<title>1. Introduction of Alzheimer’s Disease Pathology</title>
<sec id="sec1dot1-cells-08-00242">
<title>1.1. Alzheimer’s Disease Pathology and Progression</title>
<p>Alzheimer’s disease (AD) is a very common, incurable age-associated and economically costly disease characterized by progressive neurodegeneration, which causes deterioration and damage of neurons within the cerebral cortex, loss of memory, and cognitive decline [<xref ref-type="bibr" rid="B1-cells-08-00242">1</xref>]. It is the most common type of dementia and over 30 million people are suffering from this disease all over the world [<xref ref-type="bibr" rid="B2-cells-08-00242">2</xref>]. About 500,000 people die of AD every year and this number increases year by year. Currently, no effective treatments or available drugs can cure AD and the total costs in 2010 were around $172 billion in the United States [<xref ref-type="bibr" rid="B2-cells-08-00242">2</xref>], which makes it a heavy economic burden not only on the dementia patients but also on our global society. Most of clinical cases in AD develop late-onset symptoms (after the age of 65), also called sporadic AD (SAD). And about 2–5% of disease burden is an early-onset type, called familial AD (FAD). FAD is related to genetic mutations, such as mutations in amyloid precursor protein (APP), presenilin-1 (PS1), and presenilin-2 (PS2) [<xref ref-type="bibr" rid="B3-cells-08-00242">3</xref>]. The gene of PS1 encodes the catalytic subunit of γ-secretase that mediates APP cleavage for the generation of amyloid β42 (Aβ42) peptides [<xref ref-type="bibr" rid="B4-cells-08-00242">4</xref>].</p>
<p>AD is identified by three cardinal features in human brain: Aβ plaques, neurofibrillary tangles (NFTs), and neuron loss. Aβ plaques are usually formed because of the increased production or deficient clearance of neuronal Aβ caused by unknown reasons. APP is proteolyzed to the soluble and nontoxic Aβ monomers by β- and γ-secretases. The monomeric Aβ peptides then aggregate to form toxic Aβ oligomers and further generate the insoluble fibrils, which ultimately form the plaques (<xref ref-type="fig" rid="cells-08-00242-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B5-cells-08-00242">5</xref>]. Some extracellular matrix (ECM) components, e.g., heparan sulfate proteoglycans (HSPG), are considered to promote extracellular formation of amyloid plaques [<xref ref-type="bibr" rid="B6-cells-08-00242">6</xref>]. In addition, a healthy body has the mechanism to remove Aβ peptides and balance their generation and clearance. For instance, matrix metalloproteinase 3 (MMP3), a collagen IV proteinase, could degrade Aβ components [<xref ref-type="bibr" rid="B7-cells-08-00242">7</xref>,<xref ref-type="bibr" rid="B8-cells-08-00242">8</xref>]. Also, a defective clearance of Aβ and an unbalance between Aβ generation and clearance have been demonstrated in SAD [<xref ref-type="bibr" rid="B9-cells-08-00242">9</xref>]. Thus, the peculiar generation and flawed removal of Aβ peptides cause Aβ accumulation. The more accumulations of Aβ peptides occur, the more senile plaques are formed in the human brain.</p>
<p>The NFTs in AD are composed of paired helical filaments consisting of hyperphosphorylated tau (p-tau), a protein associated with the microtubules [<xref ref-type="bibr" rid="B10-cells-08-00242">10</xref>]. The normal form of tau is soluble, whereas it depicts strong ability to assemble and become insoluble under physiological conditions. The over phosphorylation of tau contributes to its disassembly from microtubules and its aggregation to form insoluble fibers, that is, the NFTs. Protein kinases, such as mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3), and Jun N-terminal kinase/stress-activated protein kinases (JNK/SAPK), could upregulate phosphorylation of tau. Many studies support the notion that Aβ may interplay with tau-derived NFT formation, while critical questions about Aβ-induced tau pathology in AD are still unanswered. Overall, the perturbation of tau kinases and tau phosphatases leads to the abnormal hyperphosphorylation of tau, which results in NFT generation and toxicity in neurons.</p>
<p>The Aβ plaque and NFT formation show toxicity to neuronal cells. However, the causes of synaptic dysfunctions and selective loss of vulnerable neurons, particularly the subtypes, such as pyramidal, cholinergic, noradrenergic, and serotonergic neurons, remain elusive [<xref ref-type="bibr" rid="B11-cells-08-00242">11</xref>]. Studies show that Aβ plaques could trigger an inflammatory process by increasing the secretion of pro-inflammatory factors, e.g., IL-6 and TNF-α, which impair microglia and the surrounding neural cells, and finally result in neurodegeneration and neuron loss [<xref ref-type="bibr" rid="B12-cells-08-00242">12</xref>,<xref ref-type="bibr" rid="B13-cells-08-00242">13</xref>]. Based on the Aβ plaque deposition and cortical NFT formation, AD initiates when the connection between entorhinal cortex and hippocampus begins to disappear at the transentorhinal stage [<xref ref-type="bibr" rid="B5-cells-08-00242">5</xref>,<xref ref-type="bibr" rid="B14-cells-08-00242">14</xref>]. Other neuronal cells, such as GABAergic interneurons, show their function loss during the advanced stage of AD, i.e., the isocortical stage.</p>
</sec>
<sec id="sec1dot2-cells-08-00242">
<title>1.2. Current Challenges and the Demand for a Good AD Model</title>
<p>Although the pathophysiological changes of AD are characterized, it is unclear what factors induce the disease and how selective neuronal loss in AD is caused. Many hypotheses have been proposed for the causes of pathological characteristics [<xref ref-type="bibr" rid="B5-cells-08-00242">5</xref>,<xref ref-type="bibr" rid="B9-cells-08-00242">9</xref>]. These hypotheses include: (1) amyloid hypothesis, which posits that the gene mutations of APP and PS1/2 induce the overexpression or deficient removal of Aβ toxic species, and thus lead to the other two cardinal changes associated with AD (<xref ref-type="fig" rid="cells-08-00242-f001">Figure 1</xref>); (2) tau hypothesis, which believes that the hyperphosphorylated tau protein disassembles from microtubules and subsequently induces neuronal death (<xref ref-type="fig" rid="cells-08-00242-f001">Figure 1</xref>); (3) unknown triggering hypothesis, which postulates that some uncertain factors lead to the neurodegeneration, both directly and indirectly, through the formation of plaques and tangles. The last case seems to incorporate both the amyloid and tau hypotheses to interpret the etiology of AD. Although both amyloid and tau hypotheses could explain some of the pathological hallmarks and clinical observations about AD, there is still a controversy over which one occurs first. Thus, it is necessary to establish the disease models of AD, given that it is difficult to obtain patient brain samples.</p>
<p>To date, the modeling of AD for mechanistic and pathological studies mainly relies on non-human animal models and non-neuronal human cells. Non-neuronal cells usually lack the specific cellular structures of neurons and fail to recapitulate the signaling pathway and other physiology of neurons. Therefore, they cannot capture the three pathological changes in AD [<xref ref-type="bibr" rid="B15-cells-08-00242">15</xref>]. The transgenic animal models, usually the mice, have been developed for discovering genetic mutations in FAD [<xref ref-type="bibr" rid="B16-cells-08-00242">16</xref>,<xref ref-type="bibr" rid="B17-cells-08-00242">17</xref>,<xref ref-type="bibr" rid="B18-cells-08-00242">18</xref>]. To some extent, these models could interpret the pathogenicity of Aβ accumulation, plaque formation, and tauopathy. For instance, one study has developed a transgenic AD mouse model with a mutation in APP [<xref ref-type="bibr" rid="B17-cells-08-00242">17</xref>]. The model showed senile plaque formation and disconnection of synapses, but the presence of NFTs and neuronal loss was never found. Although animal models displayed the benefits for understanding AD neuropathology, they fail to reflect human brain anatomy, genetics, and the AD-associated neuron loss. More importantly, pharmacological testing and candidate drug target screening for AD using these animal models have shown no successful development for AD therapeutics till now [<xref ref-type="bibr" rid="B19-cells-08-00242">19</xref>]. Therefore, a more robust and suitable model that could capture all the three cardinal characteristics of AD is demanded. Recently, human adult neural stem cell-derived models through 3D culture in vitro, although limited by the cell source, were found to increase Aβ plaque depositions and tau phosphorylation [<xref ref-type="bibr" rid="B20-cells-08-00242">20</xref>,<xref ref-type="bibr" rid="B21-cells-08-00242">21</xref>]. In another study, Choi et al. reported a 3D thin-layer culture system by embedding human neural stem cells into Matrigel to model AD [<xref ref-type="bibr" rid="B22-cells-08-00242">22</xref>]. The overexpression of FAD mutations in APP and PS1 in embedded cells could induce both extracellular Aβ plaque and phosphorylated tau aggregation in the soma and neurites. These studies accurately paved the way for using human induced pluripotent stem cells (hiPSCs), a more reproducible and scalable cell type, to model AD in vitro.</p>
</sec>
</sec>
<sec id="sec2-cells-08-00242">
<title>2. Human Pluripotent Stem Cells for Modeling AD</title>
<p>Human PSCs (hPSCs) include human embryonic stem cells (ESCs) derived from blastocysts and hiPSCs reprogrammed from somatic cells. HPSCs show the properties of unlimited self-renewal and potent differentiation capacity. Theoretically, hPSCs could give rise to the three-germ layers, including ectoderm, endoderm, and mesoderm, and generate every cell type in the body (e.g., neurons, heart, pancreatic, and liver cells). HiPSCs were pioneered by Shinya Yamanaka’s lab in 2006 that the introduction of four reprogramming factors including Oct4, Sox2, c-Myc, and Klf4 (also dubbed Yamanaka factors) could convert adult somatic cells into PSCs [<xref ref-type="bibr" rid="B23-cells-08-00242">23</xref>]. Using hiPSCs to model AD shows great advantages compared to other cell lines or model systems. First, patient-specific cell lines can be easily established just through collecting biopsy from patients (e.g., drops of blood or a piece of skin) and reprogramming the tissue to hiPSCs (<xref ref-type="fig" rid="cells-08-00242-f002">Figure 2</xref>). Therefore, the ethical controversy using human embryos for human ESCs can be avoided. For AD, the patient-specific hiPSCs loaded with gene mutations can easily recapitulate the mechanism of disease progression, especially for the early-onset type. Thus, the transgenic technology for specific genetic manipulation used in animal models becomes unnecessary. HiPSCs are also clinically advantageous since the use of autologous tissue ideally surpasses the patient’s immune rejection. Moreover, hiPSCs with unlimited self-renewal capacity could help to provide large numbers of patient-specific neuronal cells for in vitro research and clinical applications.</p>
<sec id="sec2dot1-cells-08-00242">
<title>2.1. AD Models Using hPSCs</title>
<p>Generally, three methods are utilized to establish AD pathological phenotype using hPSCs (summarized in <xref ref-type="table" rid="cells-08-00242-t001">Table 1</xref>). The first method is chemical induction, in which extrinsic chemicals, such as Aβ42 oligomers and aftin5 (an Aβ42 inducer), are used to treat healthy hPSC-derived neural cells and induce AD-related phenotypes [<xref ref-type="bibr" rid="B24-cells-08-00242">24</xref>,<xref ref-type="bibr" rid="B25-cells-08-00242">25</xref>,<xref ref-type="bibr" rid="B26-cells-08-00242">26</xref>]. The addition of extrinsic chemicals to the normal hPSC-derived neurons could recapitulate some AD events, such as cytotoxicity of neuronal cells. However, the progression and some important AD pathologies, such as extracellular Aβ plaque formation, are difficult to recapitulate. The second method is to use genetic tools, such as lentivirus vectors or CRISPR-Cas9 gene-editing system, to overexpress AD-related genes, such as APP, PS1/2, and apolipoprotein E3/E4 (APOE3/E4), in hPSC-derived cells [<xref ref-type="bibr" rid="B27-cells-08-00242">27</xref>,<xref ref-type="bibr" rid="B28-cells-08-00242">28</xref>,<xref ref-type="bibr" rid="B29-cells-08-00242">29</xref>]. Using human ESC-derived neurons with recombinant human APOE2, APOE3, or APOE4, Huang et al. showed that all three APOE isoforms could upregulate APP and Aβ production but with different efficacy (APOE4 &gt; APOE3 &gt; APOE2) [<xref ref-type="bibr" rid="B29-cells-08-00242">29</xref>]. Park et al. co-cultured neurons and astrocytes derived from hPSCs overexpressing FAD-APP mutations with immortalized SV40 microglia in a microfluidics-based system to study neuro-inflammatory activity in AD [<xref ref-type="bibr" rid="B30-cells-08-00242">30</xref>]. For this approach, overexpression of mutant proteins is needed to induce AD phenotype.</p>
<p>The third method is to use AD patient-specific iPSCs carrying AD phenotype and mutations [<xref ref-type="bibr" rid="B42-cells-08-00242">42</xref>,<xref ref-type="bibr" rid="B59-cells-08-00242">59</xref>]. HiPSCs derived from familial and sporadic AD patients have been differentiated into various types of neuronal cells for studying specific AD pathologies (<xref ref-type="table" rid="cells-08-00242-t001">Table 1</xref>). The patients generally had genetic mutations in APP, PS1, or PS2, in the case of FAD, and mutations in APOE3/E4 for SAD. Most of the hPSC-derived AD models used either 2D or embryoid body/neurosphere differentiation protocols to generate forebrain neurons, such as cortical glutamatergic neurons, GABAergic interneurons, or cholinergic neurons. The neuronal cells were characterized through gene and/or neuronal marker expression and tested for action potentials and calcium-handling ability for functional assessments. The AD-related pathology including elevated Aβ42 production and hyperphosphorylated tau was indicated in these models [<xref ref-type="bibr" rid="B71-cells-08-00242">71</xref>,<xref ref-type="bibr" rid="B72-cells-08-00242">72</xref>].</p>
<p>There are two main classes of mutations for familial AD: (1) mutations in APP; and (2) the mutations in PS1 or PS2 [<xref ref-type="bibr" rid="B73-cells-08-00242">73</xref>]. Aβ is a cleavage product of APP, so the dysfunction of APP processing can cause AD (<xref ref-type="fig" rid="cells-08-00242-f001">Figure 1</xref>). PS1/PS2 mediate the regulated proteolytic events of several proteins including γ-secretase [<xref ref-type="bibr" rid="B39-cells-08-00242">39</xref>], which plays an important role in Aβ generation. Mutations in PS1/PS2 also lead to Aβ plaque accumulation. Human iPSC lines were derived from familial (APP mutation) and sporadic AD patients and differentiated into cortical neurons (expressing TBR1 and SATB2) [<xref ref-type="bibr" rid="B37-cells-08-00242">37</xref>]. In FAD-derived cells, extracellular Aβ42 increased along with the decrease in intracellular Aβ2 compared to control neural cells. For SAD-derived cells, extracellular Aβ42 did not change while intracellular Aβ42 decreased compared to control of neural cells. Astrocytes also accumulated intracellular Aβ, which increased endoplasmic reticulum (ER) stress and reactive oxygen species (ROS). To improve ER stress and inhibit ROS generation, drugs including BSI, DHA, NSC23766, and dibenzoylmethane were evaluated. DHA decreased BiP (an HSP70 molecular chaperone located in the lumen of the ER) protein level, cleaved caspase 4 and peroxiredoxin-4, and decreased ROS generation. Differential response to DHA was observed for different patient-specific hiPSCs, indicating that DHA may be used for a subset of AD patients.</p>
<p>To evaluate if hiPSCs can recapitulate AD phenotype in the patients and understand the relationship between APP processing and tau phosphorylation, hiPSCs were derived from two familial (mutations in APP) and two sporadic AD patients [<xref ref-type="bibr" rid="B36-cells-08-00242">36</xref>]. Neurons from AD patients (two familial and one sporadic) had elevated levels of Aβ40, p-tau, and active glycogen synthase kinase-3β (aGSK-3β). β-secretase inhibitors, but not γ-secretase inhibitors, reduced p-tau and aGSK-3β levels. In AD, synaptic loss is one pathological observation, and the decreased synapsin I is usually observed in the affected human brain. In this study, no synaptic loss was observed and an extended culture period may be required to observe synaptic loss.</p>
<p>Neural progenitor cells (NPCs) derived from hiPSCs from PS1 FAD patients were also characterized [<xref ref-type="bibr" rid="B39-cells-08-00242">39</xref>]. The differentiation from hiPSCs used monolayer-based protocol with dual SMAD inhibition for 14 days. The derived NPCs displayed normal electrophysiology. However, an increased ratio of Aβ42/Aβ40 was observed in the conditioned medium compared to the control cell lines. Genetic profiling identified the genes that were differentially regulated due to PS1 mutations in order to find the molecules that might have a developmental role in FAD pathology. Three targets were found, including NLRP2, ASB2, and NDP. In particular, NDP expression decreased in the hippocampus of the late-onset AD brains. Moreover, synaptic dysfunction was observed in hiPSC-derived cortical neurons with autosomal dominant AD mutations or trisomy of chromosome 21 [<xref ref-type="bibr" rid="B58-cells-08-00242">58</xref>]. The released Aβ peptides from the FAD neurons with APP or PS1 mutations blocked hippocampal long-term potentiation (LTP), while neurons with trisomy 21 inhibited LTP through extracellular tau [<xref ref-type="bibr" rid="B58-cells-08-00242">58</xref>]. In another study, APOE4-expressing neurons showed elevated levels of tau phosphorylation, which was not related to the increased Aβ production, and the cells displayed GABAergic neuron degeneration [<xref ref-type="bibr" rid="B66-cells-08-00242">66</xref>].</p>
</sec>
<sec id="sec2dot2-cells-08-00242">
<title>2.2. Neural Tissue Patterning of hPSCs</title>
<p>The advancements using hPSCs to model AD started with the generation of neuronal cells or tissues that are directly affected by the disease through neural patterning (<xref ref-type="fig" rid="cells-08-00242-f002">Figure 2</xref>). The key to success of this utilization is to efficiently generate specific neuronal subtypes or brain-like tissues from hPSCs. Neural tissue patterning is a complex process governed by intrinsic and extrinsic factors including morphogens and cell-ECM interactions. During the development of mammalian brain, early neural progenitors of the neural tube are derived through the inhibition of bone morphogenetic protein (BMP) and activin signaling. The cells are then specified into neuronal subtypes of each brain region along the rostral-caudal axis by tuning Wnt and retinoic acid (RA) signaling pathways, and along the dorsal-ventral axis mainly by the gradient of sonic hedgehog (SHH) proteins. Based on this knowledge, protocols utilizing the morphogens to mimic brain development have been established to produce brain region-specific neuronal subtypes derived from hPSCs (<xref ref-type="fig" rid="cells-08-00242-f003">Figure 3</xref>). For example, cortical glutamatergic neurons and GABAergic neurons from hPSCs were acquired by the modulation of SHH and fibroblast growth factor (FGF)-2 signals [<xref ref-type="bibr" rid="B25-cells-08-00242">25</xref>,<xref ref-type="bibr" rid="B74-cells-08-00242">74</xref>], while hindbrain/spinal motor neurons were efficiently derived through the activation of SHH, RA, and Wnt signaling pathways [<xref ref-type="bibr" rid="B75-cells-08-00242">75</xref>]. HPSC-derived spherical brain-like tissues, such as cerebral organoids with definable forebrain, midbrain, and hindbrain/spinal cord layers [<xref ref-type="bibr" rid="B76-cells-08-00242">76</xref>], and cortical spheroids with laminated regions [<xref ref-type="bibr" rid="B77-cells-08-00242">77</xref>] were generated by the default neural development without extrinsic factors. Interestingly, recent studies have obtained the whole spectrum of brain region-specific neural progenitors and neuronal subtypes from hiPSCs [<xref ref-type="bibr" rid="B78-cells-08-00242">78</xref>,<xref ref-type="bibr" rid="B79-cells-08-00242">79</xref>], which indicates the remarkable value of hiPSC-based models for the study and treatment of patient-specific neurological diseases. For AD, the Aβ deposition, tau tangles, and neuronal loss ultimately occur in the cerebral cortex, leading to the cortical symptoms related to language, attention, and visuospatial orientation. Therefore, studies modeling AD with hiPSCs often begin with the generation of forebrain cortical neurons. Differentiation to forebrain neuronal fates is based on the “default” induction strategies without exogenous patterning factors after dual-SMAD inhibition in a monolayer culture or embryoid body (EB)-based culture [<xref ref-type="bibr" rid="B77-cells-08-00242">77</xref>,<xref ref-type="bibr" rid="B80-cells-08-00242">80</xref>].</p>
</sec>
<sec id="sec2dot3-cells-08-00242">
<title>2.3. A Novel Neural Patterning Method: Organoid Technology</title>
<p>The organoid systems derived from EB-based cultures emerge as a mixed cell population in a 3D platform. Relying on the intrinsic ability of self-organization of hiPSCs, and sometimes with the help of suitable exogenous factors (e.g., Matrigel), organoids recapitulate a large number of biological events in vivo [<xref ref-type="bibr" rid="B82-cells-08-00242">82</xref>,<xref ref-type="bibr" rid="B83-cells-08-00242">83</xref>]. Organoids are 3D spatial organization including heterogeneous tissue-specific cells, cell-cell interactions, and cell-ECM interactions, and exhibit certain physiological functions similar to tissues or organs in human body [<xref ref-type="bibr" rid="B84-cells-08-00242">84</xref>]. During organoid formation, ECM is one of the most important patterning factors that regulate and assist the self-organization and differentiation of stem cells within the organoids (<xref ref-type="fig" rid="cells-08-00242-f004">Figure 4</xref>) [<xref ref-type="bibr" rid="B85-cells-08-00242">85</xref>]. ECMs, either secreted by stem cells or derived from artificial scaffolds, provide physical supports for cell attachment and organization and additional supplementation of signaling cues for cell growth and differentiation [<xref ref-type="bibr" rid="B86-cells-08-00242">86</xref>,<xref ref-type="bibr" rid="B87-cells-08-00242">87</xref>]. This organoid technology bridges a gap in the existing in vitro 3D culture systems by providing a robust approach for tissue patterning of stem cells and is more representative of in vivo situations [<xref ref-type="bibr" rid="B88-cells-08-00242">88</xref>,<xref ref-type="bibr" rid="B89-cells-08-00242">89</xref>,<xref ref-type="bibr" rid="B90-cells-08-00242">90</xref>].</p>
<p>The first generation of neural rosettes from human ESCs was derived in 2001 by forming spontaneously differentiated EBs and then plating EBs on coated dishes for neuroepithelial cluster formation [<xref ref-type="bibr" rid="B91-cells-08-00242">91</xref>]. Combining the EB-based rosette patterning and serum-free culture, the so-called SFEBq approach, i.e., serum-free floating culture of EB-like aggregates with quick re-aggregation, was developed and could generate remarkably large rosettes with lumens and apicobasal structures from hPSCs in 2008 [<xref ref-type="bibr" rid="B92-cells-08-00242">92</xref>]. In 2011, the self-organizing optic cups with retinal specifications from hPSCs were derived using the entirely 3D EB-based neural culture [<xref ref-type="bibr" rid="B93-cells-08-00242">93</xref>]. This study indicates that neural tissues with histologically accurate architecture could be patterned only in 3D floating culture of hPSCs. All these studies paved the road for the advent of a new neural patterning technology, that is, organoid. In 2013, Lancaster et al. derived cerebral organoids with a broad brain regionalization to model microcephaly using EB-based culture with Matrigel embedding and agitation [<xref ref-type="bibr" rid="B76-cells-08-00242">76</xref>]. The organoids could reach up to 4 mm in diameter with fluid-filled cavities that resembled ventricles rather than the small neural-tube-like lumens found in rosettes. After that, the organoid-based neural patterning methods of hPSCs have been utilized for mimicking human brain development, modeling neurological disease in vitro, and testing potential drug candidates [<xref ref-type="bibr" rid="B81-cells-08-00242">81</xref>].</p>
<p>Using the SFEBq method, multilayer structures were derived from hiPSCs with lower and upper cortical layer fates in dorsal forebrain [<xref ref-type="bibr" rid="B94-cells-08-00242">94</xref>]. The 3D aggregates can generate inhibitory neurons and display neuronal connectivity (expression of synapsin I and PSD95). Genomics study showed the correlation to the brain development at postconceptional weeks 4–10. Another 3D culture was used to generate laminated cerebral cortex-like structure from hPSCs [<xref ref-type="bibr" rid="B77-cells-08-00242">77</xref>]. The cells were induced for forebrain fate using dual SMAD inhibition for six days, followed by FGF-2/epidermal growth factor treatment for 19 days, and the maturation with brain-derived neurotrophic factor (BDNF) and NT3. At day 18, 85% PAX6+ cells and &gt;80% of FOXG1+ cells were observed. The organoid size increased from 300 µm at two weeks to 4 mm at 2.5 months. The formed human cortical spheroids corresponded to the late mid-fetal periods. The spheroids had a distinct ventricular zone and sub-ventricular zone. The cells also formed superficial cortical layers (expressing BRN2 and SATB2 for layer II-IV, emerged at day 76) and deep cortical layers (expressing CTIP2-layer V and TBR1-layer VI, showed up at day 52). The presence of GFAP+ cells showed the astrogenesis (3–8% cells). Functional characterizations include: (1) calcium imaging for spontaneous calcium spikes; (2) Na<sup>+</sup>/K<sup>+</sup> currents; and (3) the firing of action potentials. Slices of spheroids showed spontaneous synaptic activity, which can be reduced by a glutamate receptor blocker. This study demonstrated the patterning and specification of different neuronal and glial cell types which can be used for large-scale drug screening.</p>
<p>The organoid technology is a promising method to mimic human brain development and could generate brain-like tissues for modeling neurological diseases, including autosomal recessive primary microcephaly [<xref ref-type="bibr" rid="B95-cells-08-00242">95</xref>], Zika virus infection [<xref ref-type="bibr" rid="B96-cells-08-00242">96</xref>], autism spectrum disorder [<xref ref-type="bibr" rid="B97-cells-08-00242">97</xref>], Timothy syndrome [<xref ref-type="bibr" rid="B98-cells-08-00242">98</xref>], brain tumors [<xref ref-type="bibr" rid="B99-cells-08-00242">99</xref>,<xref ref-type="bibr" rid="B100-cells-08-00242">100</xref>], and others (see the review by Amin et al., 2018 [<xref ref-type="bibr" rid="B101-cells-08-00242">101</xref>]). Lots of studies have shown the feasibility of the organoid methods to model AD pathogenesis [<xref ref-type="bibr" rid="B24-cells-08-00242">24</xref>,<xref ref-type="bibr" rid="B52-cells-08-00242">52</xref>,<xref ref-type="bibr" rid="B60-cells-08-00242">60</xref>,<xref ref-type="bibr" rid="B61-cells-08-00242">61</xref>]. Our previous studies found that dynamic culture of cerebral organoids promoted cortical layer structure compared to static culture, and the 3D brain organoids from hiPSCs with PS1 M146V mutation could recapitulate some AD-related phenotype, such as Aβ secretion and neuron death [<xref ref-type="bibr" rid="B59-cells-08-00242">59</xref>,<xref ref-type="bibr" rid="B102-cells-08-00242">102</xref>]. By using hiPSCs with APOE4/E3 mutations, Lin et al. showed that APOE4 forebrain organoids displayed the increased Aβ aggregation and hyperphosphorylated tau [<xref ref-type="bibr" rid="B61-cells-08-00242">61</xref>]. Taken together, 3D hPSC-derived organoids provide structured neural tissues and specific microenvironments that can be used to model AD-associated pathology.</p>
</sec>
<sec id="sec2dot4-cells-08-00242">
<title>2.4. Effects of ECMs on Neural Patterning of hPSCs</title>
<p>The central nervous system (CNS) is characterized by a functional network of neurons, glia, and their secreted ECMs. ECMs constitute the essential physical structures for neural cells and provide diverse biochemical signals for neurogenesis, neural cell migration and differentiation, and synaptic plasticity. ECMs also play an important role in neural tissue patterning of hPSCs. Studies performed with decellularized ECMs from different PSC derivatives indicated that ECMs guided PSC differentiation into the cell types residing in the tissue from which the ECMs were derived [<xref ref-type="bibr" rid="B103-cells-08-00242">103</xref>,<xref ref-type="bibr" rid="B104-cells-08-00242">104</xref>]. The ECM-stem cell interactions are mainly mediated by integrins, a large family of heterodimeric transmembrane receptors connecting with an intracellular cytoskeleton. Thus, cell migration, organization, and differentiation could be regulated through ECM-integrin-cytoskeleton connections. For instance, the binding between α6β1 integrin and laminin is the key player for neural stem cell adhesion to the vascular structures [<xref ref-type="bibr" rid="B105-cells-08-00242">105</xref>]. ECMs may also control stem cell fate decisions through the modulation of intracellular signaling. For example, our previous study demonstrated that undifferentiated PSC-derived ECMs could upregulate Wnt/β-catenin signaling, while NPC-derived ECMs promoted neural patterning of PSCs through the inhibition of Wnt signaling pathway [<xref ref-type="bibr" rid="B106-cells-08-00242">106</xref>].</p>
<p>The biophysical properties, such as elastic modulus, geometry, and Poisson’s ratio of matrix, also impact growth, proliferation, and neural differentiation of PSCs [<xref ref-type="bibr" rid="B107-cells-08-00242">107</xref>,<xref ref-type="bibr" rid="B108-cells-08-00242">108</xref>]. Stem cells cultured on hydrogels with varied stiffness indicated that substrate elastic modulus can alter critical cellular events, such as ECM assembly, cell motility, and cell spreading [<xref ref-type="bibr" rid="B109-cells-08-00242">109</xref>,<xref ref-type="bibr" rid="B110-cells-08-00242">110</xref>,<xref ref-type="bibr" rid="B111-cells-08-00242">111</xref>]. For neural patterning, a large number of studies showed the important effects of matrix stiffness or elastic modulus (<xref ref-type="table" rid="cells-08-00242-t002">Table 2</xref>) [<xref ref-type="bibr" rid="B111-cells-08-00242">111</xref>,<xref ref-type="bibr" rid="B112-cells-08-00242">112</xref>,<xref ref-type="bibr" rid="B113-cells-08-00242">113</xref>,<xref ref-type="bibr" rid="B114-cells-08-00242">114</xref>,<xref ref-type="bibr" rid="B115-cells-08-00242">115</xref>,<xref ref-type="bibr" rid="B116-cells-08-00242">116</xref>,<xref ref-type="bibr" rid="B117-cells-08-00242">117</xref>,<xref ref-type="bibr" rid="B118-cells-08-00242">118</xref>]. Saha et al. first showed that soft substrates supported neuron differentiation from NPCs, while a higher elastic modulus (<italic>E</italic> ~ 1 to 10 kPa) promoted glial cell generation [<xref ref-type="bibr" rid="B111-cells-08-00242">111</xref>]. Leipzig et al. further demonstrated that substrates with Young’s modulus (<italic>E</italic>) below 1 kPa favored neuronal differentiation, those in the range of 1 and 3.5 kPa supported astrocytes, and above 7 kPa could enhance oligodendrocyte derivation [<xref ref-type="bibr" rid="B112-cells-08-00242">112</xref>]. By culturing hPSCs on Matrigel-coated polyacrylamide substrates, a very soft matrix (<italic>E</italic> ~ 0.1 kPa) was found to support early neural differentiation of hPSCs [<xref ref-type="bibr" rid="B119-cells-08-00242">119</xref>]. Normally, cells sense elasticity during the attachment on the substrate through focal adhesions and formation of stress fibers. Their responses to the matrix properties rely on myosin-directed contraction and cell-ECM adhesions, which involve integrins, cadherins, and other adhesion molecules [<xref ref-type="bibr" rid="B120-cells-08-00242">120</xref>]. The Poisson’s ratio is another important biophysical cue that influences stem cell behaviors, as the nuclei of ESCs exhibit a negative Poisson’s ratio in the pluripotent-state [<xref ref-type="bibr" rid="B121-cells-08-00242">121</xref>]. Our previous work found that Poisson’s ratio of matrix could confound the effects of elastic modulus on PSC neural differentiation [<xref ref-type="bibr" rid="B108-cells-08-00242">108</xref>]. In conclusion, ECMs serve as a reservoir of biochemical and biophysical factors that impact stem cell growth, organization, and differentiation.</p>
</sec>
</sec>
<sec id="sec3-cells-08-00242">
<title>3. Proteoglycans in the ECMs of AD Brain</title>
<p>The brain ECMs express low amounts of fibrous proteins, such as collagen and laminin, but high amounts of glycosaminoglycans (GAG) compared to other tissue types. The ECMs in the brain include glycoproteins and proteoglycans originated from neurons or glia. Proteoglycans (PGs) are a group of glycoproteins that carry covalently bound sulfated GAG chains which play important roles in cell differentiation, tissue morphogenesis, and phenotypic stabilization via cell-matrix adhesiveness and/or binding to growth regulators. GAGs are composed of repeating disaccharide units attached to a core protein through serine residue and carbohydrate linkage regions. Depending on the disaccharide structures, PGs can be divided into chondroitin/dermatan sulfate, heparin/heparan sulfate (HS), and keratan sulfate side chains. In the CNS, the majority of proteoglycans have either heparin sulfate or chondroitin sulfate side chains. PGs are expressed at different stages of human brain development and are produced non-homogenously by different neural cell types [<xref ref-type="bibr" rid="B144-cells-08-00242">144</xref>].</p>
<sec id="sec3dot1-cells-08-00242">
<title>3.1. Chondroitin Sulfate Proteoglycans (CSPGs) in Brain Development</title>
<p>CSPG family consists of four members: (1) lecticans, a family including aggrecan, versican, neurocan, and brevican; (2) phosphacan; (3) small leucine-rich proteoglycans, e.g., decorin and biglycan; (4) other CSPGs including neuroglycan-C and NG2 [<xref ref-type="bibr" rid="B145-cells-08-00242">145</xref>]. Distribution and expression of these CSPGs vary during human brain development. Aggrecan and versican are distributed in ECMs of various non-neuronal tissues as well as neural tissues, whereas neurocan and brevican appear to show a neural tissue-specific distribution. Versicans are found to express in the post-natal development of brains. Brevican is expressed predominantly by astrocytes, not neurons. NG2, a large transmembrane CSPG, is expressed by oligodendrocyte progenitor cells in CNS. Neurocan, a secretory CSPG, is reported to be synthesized mainly by neuronal cells.</p>
<p>The CSPGs are either secreted as ECMs or inserted to the plasma membrane of the cells. The attachment of CSPGs to the cell membrane is either through a collagenous ligand or by core proteins and cell surface-associated CSPGs such as aggrecan. The concentrations of aggrecan and brevican increase during brain development. The concentration of neurocan also increases with development to reach a peak in the early postnatal period and declines thereafter. The full-length neurocan is the major variant in pre- and early postnatal brains, while it is hardly detectable in the mature brain. Phosphacan and receptor-type protein tyrosine phosphatase are produced by both glial cells and neuronal cells. Variations in sulfate content and localization on the same GAG chains or the same core protein are tissue-specific or cell-specific. The expression of specific GAG biosynthetic and modifying enzymes by individual neural cell types dictates the type of carbohydrate modification of the core proteins expressed in each cell type [<xref ref-type="bibr" rid="B146-cells-08-00242">146</xref>].</p>
</sec>
<sec id="sec3dot2-cells-08-00242">
<title>3.2. Heparin/HSPG in Brain Development</title>
<p>Heparan sulfate proteoglycans are heavily glycosylated proteins, in which some HS and GAG chains are covalently attached to a core protein, which can be either surface proteins (e.g., syndecans/glypicans) or secreted proteins (e.g., agrin/collagen type XVIII/perlecan) [<xref ref-type="bibr" rid="B147-cells-08-00242">147</xref>]. N-Syndecan (syndecan-3), a transmembrane HSPG, has the capacity to bind to heparin-binding growth factors with a neurite-promoting activity, such as FGF-2, pleiotrophin/HBGAM, and midkine. This matrix-growth factor interaction is found to be the basis for the axonal development of neural cells. Also, N-syndecan works as a receptor molecule for pleiotrophin, which then enhances the phosphorylation of intracellular cytoskeleton-regulating molecules, such as cortactin and fyn-kinase. It was found that the association of cortactin and fyn-kinase with N-syndecan was increased after induction of long-lasting synaptic sensitivity called long-term potentiation.</p>
<p>N-syndecan regulates the neuronal activity-dependent connectivity through the fyn signaling pathway. N-syndecan, together with syndecan-2, also appears to be involved in the maturation of synapses. Syndecan-2 interacts with calcium/calmodulin-dependent serine protein kinase, a PDZ family protein that induces the formation of mature dendritic spines, and supports the development of postsynaptic specialization [<xref ref-type="bibr" rid="B148-cells-08-00242">148</xref>]. Heparin is one of the glycosaminoglycans that bind to different proteins and thereby promote various neural functions, such as preventing blood clotting, neuronal communication, and brain development.</p>
</sec>
<sec id="sec3dot3-cells-08-00242">
<title>3.3. Impacts of CSPG on AD Pathology</title>
<p>The motor and sensory areas of the cortical brain, which show cytoskeletal changes during AD development, were found to express prominent levels of CSPGs. These results suggested the importance of CSPGs on AD development, e.g., synaptic loss. Numerous molecular events occur in the post-synaptic density of an excitatory synapse in response to a train of pre-synaptic action potentials. One of these factors is the presence of peri-synaptic ECMs, a lattice of chondroitin sulfate-bearing proteoglycans, termed lecticans (e.g., aggrecan, brevican, neurocan, and versican), bound to hyaluronic acid near their N-terminus and tenascin-R near their C-terminus. Alterations in brain ECMs occur early in AD progression. The synaptic loss is observed prior to neuronal cell death, and the loss of synapses in the outer molecular layer of the hippocampal dentate gyrus is more highly correlated with cognitive impairment than other classical AD pathology including NFTs and senile plaques. ECMs can respond to network activity by incorporating secreted molecules, by shedding extracellular domains of transmembrane molecules, or by freeing products of activity-dependent proteolytic cleavage as signaling messengers.</p>
<p>Lecticans, also known as hyalectans, have been studied for their influence on the plasticity of synapses because of the elevated expression in AD patients. Lecticans are found to contribute to diminished synaptic plasticity. Involvement of CSPGs in hippocampal synaptic plasticity was confirmed using the enzyme that specifically digests chondroitin sulfates, chondroitinase ABC (ChABC) [<xref ref-type="bibr" rid="B149-cells-08-00242">149</xref>]. Injection of ChABC in young AD mice elevated lectican levels and resulted in a reversal of contextual fear memory deficits and restoration to normal long-term potentiation. ChABC treatment results in the removal of CS chains from lectican core proteins (and other CS bearing PGs). These studies demonstrated that removal of CS chains stimulated neural plasticity. Increasing evidence has demonstrated that CS-bearing ECM molecules increase with age and are associated with AD. CS-bearing PGs bind to Aβ, but it remains unknown whether Aβ binds to brain-derived lecticans. Injection of ChABC increased synaptic density surrounding plaques and reduced Aβ burden in the s/m of the hippocampus [<xref ref-type="bibr" rid="B150-cells-08-00242">150</xref>].</p>
</sec>
<sec id="sec3dot4-cells-08-00242">
<title>3.4. Impacts of Heparin/HSPGs on AD Pathology</title>
<p>HSPGs are found to grow concomitantly with amyloid filament formation. HSPGs have a negative charge and thereby concentrate on the ligands and protect them from proteolysis while making insoluble complexes [<xref ref-type="bibr" rid="B151-cells-08-00242">151</xref>]. Heparin and HSPGs regulate the activity of a number of proteases involved in AD. HSPGs promote Aβ aggregation, stabilize Aβ fibrils, and inhibit Aβ degradation. Perlecan and agrin are found to be the important HSPGs that are involved in the pathogenesis and localized with Aβ deposits in AD brain. Perlecan accelerates Aβ fibril formation and maintains the Aβ fibril stability by using Perlecan’s HS-GAG chains [<xref ref-type="bibr" rid="B152-cells-08-00242">152</xref>]. Agrin also binds to Aβ and accelerates fibril formation and protects fibrillar Aβ from proteolysis (<xref ref-type="fig" rid="cells-08-00242-f005">Figure 5</xref>) [<xref ref-type="bibr" rid="B153-cells-08-00242">153</xref>]. HSPGs bind Aβ with high affinity and promote intracellular Aβ uptake in multiple cell types and thereby increase the cytotoxicity [<xref ref-type="bibr" rid="B154-cells-08-00242">154</xref>].</p>
<p>HSPGs are also the target of Aβ-induced oxidative stress production. Studies propose that minimal chain length is a prerequisite for efficient fibril polymerization and deposition. Fragmentation of HS using heparinase III was found to inhibit the polymerization and deposition of amyloid peptides [<xref ref-type="bibr" rid="B155-cells-08-00242">155</xref>]. Heparinase is a glucuronidase that specifically cleaves heparan sulfate, thereby preventing Aβ-HSPG interactions. The formed HS oligosaccharides then bind amyloid monomers to prevent them from polymerizing and assembling into larger aggregates. Treatment of cells with heparinase III also reduced the HSPG-based Aβ-induced ROS production.</p>
<p>HSPGs modulate the Aβ-associated neuroinflammation and Aβ clearance from the human brain. Several in vitro studies indicated the interaction of Aβ with GAGs including HS and heparin, a HS analogue with a higher sulfation degree [<xref ref-type="bibr" rid="B156-cells-08-00242">156</xref>]. All those studies describe that the N-terminus of Aβ is a HS-binding motif and this sequence supports the interaction between Aβ and HSPGs [<xref ref-type="bibr" rid="B157-cells-08-00242">157</xref>]. Studies also suggest that the Aβ peptides compete with FGF-2 for HS binding site. The interaction depends on several factors, such as the sulfation pattern, chain length of the GAGs, and the pH. The higher sulfation in heparin boosted the affinity and the degree of Aβ-HS complex formation was higher compared to Aβ-HSPG complex. Lower binding of heparin fragments shorter than 6-sugar units to Aβ also suggested the requirement of GAG chain length for the interaction [<xref ref-type="bibr" rid="B158-cells-08-00242">158</xref>]. It is also proposed that the Aβ-HS interaction is mutually protective because HS is protected from heparanase degradation and Aβ is protected from protease degradation.</p>
<p>Cellular degradation of HSPGs using heparanase (an endo-β-glucuronidase that specifically cleaves HS side chains of HSPGs) decreased the cytotoxicity of Aβ peptides on the cells [<xref ref-type="bibr" rid="B154-cells-08-00242">154</xref>]. Aβ clearance from the cells is performed in different ways, including degradation by proteolytic enzymes or receptor-mediated Aβ transport across the blood-brain barrier, in which the main receptor is low-density lipoprotein receptor-related protein-1 (LRP-1) [<xref ref-type="bibr" rid="B159-cells-08-00242">159</xref>,<xref ref-type="bibr" rid="B160-cells-08-00242">160</xref>]. The complex interactions of Aβ precursor protein ApoE, LRP-1, and HSPG facilitate Aβ internalization. Recent studies found that HSPGs and LRP-1 mediate Aβ internalization in a seemingly cooperative manner, in which HSPGs regulate Aβ binding to cell surface through LRP-1 [<xref ref-type="bibr" rid="B159-cells-08-00242">159</xref>]. These findings suggest that cell surface HS mediates Aβ internalization and toxicity. Tau binding and internalization also depend on HSPGs, which are critical mediators of tau fibril internalization. Tau binding to HSPGs is required for transcellular propagation [<xref ref-type="bibr" rid="B161-cells-08-00242">161</xref>]. Further understanding of the interactions between ECM molecules and Aβ peptides and their effects on neuronal differentiation should help to develop new treatment methods for AD.</p>
</sec>
<sec id="sec3dot5-cells-08-00242">
<title>3.5. Heparin-Based Therapy for Neural Degeneration</title>
<p>Aβ-related activation and the followed neuroinflammation are dependent on the region 1–11 of the peptide [<xref ref-type="bibr" rid="B162-cells-08-00242">162</xref>]. Related studies of the molecules that have the ability to pharmacologically target this region indicate the possible therapeutic effects of heparin [<xref ref-type="bibr" rid="B163-cells-08-00242">163</xref>]. In vitro treatment of neurons with heparin reduced Aβ-associated cytotoxicity, revealing the capability of heparin on AD treatment. Heparin, which has been widely used as an anticoagulant in clinical use, has the capability to bind to the region 12–17 of Aβ (HHQK) [<xref ref-type="bibr" rid="B157-cells-08-00242">157</xref>], near to the contact and complement activation residues. The heparin-binding regions of these proteins are characterized by clusters of arginines and lysines. These clusters form centers of highly positive charge density that electrostatically interact with the acidic groups of heparin.</p>
<p>The binding of heparin to the regions of Aβ occurs as electrostatic interactions between cationic sites of Aβ and anionic sulfate residues of heparin. This causes steric changes in the Aβ and influences the biological function, which in turn reduces the inflammation of neural cells by inhibiting Aβ complement and contact systems and thereby reduces the neurodegeneration. Complement and contact systems are related inflammatory cascades and are dependent on the reciprocal activation. These systems share a major inhibitor factor (C1 INH) with each other (<xref ref-type="fig" rid="cells-08-00242-f006">Figure 6</xref>), which is downregulated in AD brain. Inhibition of complement activation by heparin might also be due to the potentiation of C1-1NH. C1-1NH attaches to the enzymes and works as an inhibitor of spontaneous activation of the complementary system. The addition of low molecular weight heparin reduced plaques and Aβ accumulation in a mouse AD model [<xref ref-type="bibr" rid="B164-cells-08-00242">164</xref>]. Association between heparin and the Aβ peptides was found to be pH-dependent. Heparin-binding to the peptides reduced the concentration of the peptides and the expression of kinnogen.</p>
<p>Biologically active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) interacts directly with HS/heparin and has a high relative affinity for these polysaccharides. It has been reported that heparin inhibits BACE1 activity in vitro and thereby regulates the production of Aβ peptides [<xref ref-type="bibr" rid="B163-cells-08-00242">163</xref>,<xref ref-type="bibr" rid="B165-cells-08-00242">165</xref>]. It is also suggested that Aβ is a metalloprotein that expresses both high and low metal affinity sites. The AD patients are characterized by elevated levels of copper and zinc in the hippocampal region. These metals have been found to accelerate the accumulation of Aβ and promote the ROS release to the cells. Cu<sup>2+</sup> acts as a bridge between anionic groups on HSPGs and cationic groups of the NFTs. It was also found that free carboxyl groups are required for HSPG binding to NFTs. Heparin can bind to the extracellular superoxide dismutase, a homotetrameric Cu<sup>2+</sup> and Zn<sup>2+</sup> containing glycoprotein, and regulate the activity of these metals which reduce accumulation of Aβ peptides (<xref ref-type="fig" rid="cells-08-00242-f006">Figure 6</xref>).</p>
</sec>
</sec>
<sec id="sec4-cells-08-00242">
<title>4. Studying ECM Effects in hiPSC-Derived Forebrain Organoids</title>
<p>Combining the knowledge of forebrain organoids and the ECM development in AD pathology, our studies used heparin (competes for Aβ affinity with HSPG), heparinase III (digests HSPGs), chondroitinase (digests CSPGs), and hyaluronic acid (HA) to treat the cortical and hippocampal forebrain spheroids/organoids exposed to Aβ42 oligomers [<xref ref-type="bibr" rid="B166-cells-08-00242">166</xref>]. Briefly, cortical spheroids were generated using dual SMAD inhibition followed with FGF-2 and cyclopamine (an Shh inhibitor). In the case of hippocampal differentiation, the hiPSCs were treated with dual SMAD inhibitors, cyclopamine, and IWP4 (a Wnt inhibitor), followed by treatment with CHIR99021 (a Wnt activator) and BDNF. Exogenous addition of Aβ42 oligomers was found to reduce the expression of β-tubulin III, suggesting the associated neuronal cell death. The treatments of ECM-related molecules with Aβ42 oligomers promoted β-tubulin III expression, indicating the protective effect of these ECM related molecules. Further analysis on the forebrain and hippocampal markers revealed that ECM enzymes were capable of rescuing TBR1+ cells in cortical forebrain spheroids and PROX1+ neurons in the hippocampal spheroids in the presence of Aβ42 oligomers. These results suggest the necessity of further evaluation of various brain ECMs on forebrain spheroid patterning and cell survival and the related neurological disorders to derive better therapeutic interventions. In addition, heparin-conjugated HA hydrogels were synthesized and characterized [<xref ref-type="bibr" rid="B107-cells-08-00242">107</xref>]. A comparative study with heparin-HA hydrogels with varying modulus reveals that the lower modulus (300–400 Pa) hydrogel supports the forebrain fate whereas the higher modulus (1000–1300 Pa) hydrogel supports hindbrain fate of hiPSCs. This patterning effects may be regulated through modulation of the Hippo/YAP signaling.</p>
</sec>
<sec id="sec5-cells-08-00242" sec-type="conclusions">
<title>5. Conclusions and Perspectives</title>
<p>Recently, the findings of adult neurogenesis in humans have sharply declined, which raises questions about animal models to study human central nervous system [<xref ref-type="bibr" rid="B167-cells-08-00242">167</xref>]. The emerging hPSC technology and organoid methods represent promising opportunities to investigate the development of human brain and neurological diseases. These stem cell-based organoid systems have recapitulated some biological events, such as temporal and spatial organization of brain tissues, neuronal-glial cell interactions, and cell-matrix interactions. However, these models need to show promise to reveal new features of normal and pathological phenomena of neurogenesis. One aspect of the interests is that the patient-derived hPSCs with mutations, such as APP or PS1/PS2, could be used to study the roles of specific genes in FAD development and progression. Another aspect is that organoids provide a more advanced in vitro tool to investigate complex niche interactions, such as how HSPGs are involved in Aβ pathogenesis. While the organoid models have great advantages, they are also challenged by the low homogeneity and reproducibility. The brain organoids may be different from each other not only in size but also structure, which makes it difficult to control the quality and predict the readouts. Future improvements, such as novel biomaterials combined with new culture system design (e.g., microfluidics), may be utilized to better control neural patterning in a more accurate and predictable way.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank Liqing Song for her help with checking references. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Y.Y. wrote the first half of the manuscript, summarized tables, and prepared some figures. J.B. wrote the second half of the manuscript and prepared some figures. M.M. helped literature review. Y.L. conceived the projects, wrote, and revised the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This work is supported by FSU start up fund, FSU Bridge Grant, NSF BRIGE Award (No. 1342192), NSF Career Award (No. 1652992 to Y.L.), and by NIH R03NS102640 (Y.L.).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-cells-08-00242">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stelzmann</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Norman Schnitzlein</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reed Murtagh</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>An English translation of Alzheimer’s 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde”</article-title>
<source/>Clin. Anat.
          <year>1995</year>
<volume>8</volume>
<fpage>429</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1002/ca.980080612</pub-id>
<pub-id pub-id-type="pmid">8713166</pub-id>
</element-citation>
</ref>
<ref id="B2-cells-08-00242">
<label>2.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>
<source/>Dementia: A Public Health Priority
          <publisher-name>World Health Organization</publisher-name>
<publisher-loc>Genève, Switzerland</publisher-loc>
<year>2012</year>
</element-citation>
</ref>
<ref id="B3-cells-08-00242">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtzman</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Goate</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: The challenge of the second century</article-title>
<source/>Sci. Transl. Med.
          <year>2011</year>
<volume>3</volume>
<fpage>77sr71</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3002369</pub-id>
<pub-id pub-id-type="pmid">21471435</pub-id>
</element-citation>
</ref>
<ref id="B4-cells-08-00242">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bekris</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.-E.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Genetics of Alzheimer disease</article-title>
<source/>J. Geriatr. Psychiatry Neurol.
          <year>2010</year>
<volume>23</volume>
<fpage>213</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1177/0891988710383571</pub-id>
<pub-id pub-id-type="pmid">21045163</pub-id>
</element-citation>
</ref>
<ref id="B5-cells-08-00242">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Neuroprotective therapeutics for Alzheimer’s disease: Progress and prospects</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2011</year>
<volume>32</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2010.12.007</pub-id>
<pub-id pub-id-type="pmid">21256602</pub-id>
</element-citation>
</ref>
<ref id="B6-cells-08-00242">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Horssen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wilhelmus</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Heljasvaara</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pihlajaniemi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wesseling</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>de Waal</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Verbeek</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Collagen XVIII: A Novel Heparan Sulfate Proteoglycan Associated with Vascular Amyloid Depositions and Senile Plaques in Alzheimer’s Disease Brains</article-title>
<source/>Brain Pathol.
          <year>2002</year>
<volume>12</volume>
<fpage>456</fpage>
<lpage>462</lpage>
<pub-id pub-id-type="doi">10.1111/j.1750-3639.2002.tb00462.x</pub-id>
<pub-id pub-id-type="pmid">12408231</pub-id>
</element-citation>
</ref>
<ref id="B7-cells-08-00242">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meighan</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Meighan</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Zornes</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity</article-title>
<source/>J. Neurochem.
          <year>2006</year>
<volume>96</volume>
<fpage>1227</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03565.x</pub-id>
<pub-id pub-id-type="pmid">16464240</pub-id>
</element-citation>
</ref>
<ref id="B8-cells-08-00242">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mlekusch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Humpel</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Matrix metalloproteinases-2 and-3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels</article-title>
<source/>Neurosci. Lett.
          <year>2009</year>
<volume>466</volume>
<fpage>135</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2009.09.043</pub-id>
<pub-id pub-id-type="pmid">19786072</pub-id>
</element-citation>
</ref>
<ref id="B9-cells-08-00242">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.-F.</given-names>
</name>
</person-group>
<article-title>Accumulated amyloid-β peptide and hyperphosphorylated tau protein: Relationship and links in Alzheimer’s disease</article-title>
<source/>J. Alzheimer Dis.
          <year>2009</year>
<volume>16</volume>
<fpage>15</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2009-0960</pub-id>
<pub-id pub-id-type="pmid">19158417</pub-id>
</element-citation>
</ref>
<ref id="B10-cells-08-00242">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Köpke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease</article-title>
<source/>J. Biol. Chem.
          <year>1993</year>
<volume>268</volume>
<fpage>24374</fpage>
<lpage>24384</lpage>
<pub-id pub-id-type="pmid">8226987</pub-id>
</element-citation>
</ref>
<ref id="B11-cells-08-00242">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Pharmacotherapy for Alzheimer’s disease: Progress and prospects</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2002</year>
<volume>23</volume>
<fpage>426</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-6147(02)02056-4</pub-id>
<pub-id pub-id-type="pmid">12237155</pub-id>
</element-citation>
</ref>
<ref id="B12-cells-08-00242">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prokop</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Heppner</surname>
<given-names>F.L.</given-names>
</name>
</person-group>
<article-title>Microglia actions in Alzheimer’s disease</article-title>
<source/>Acta Neuropathol.
          <year>2013</year>
<volume>126</volume>
<fpage>461</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-013-1182-x</pub-id>
<pub-id pub-id-type="pmid">24224195</pub-id>
</element-citation>
</ref>
<ref id="B13-cells-08-00242">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heppner</surname>
<given-names>F.L.</given-names>
</name>
<name>
<surname>Ransohoff</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Immune attack: The role of inflammation in Alzheimer disease</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2015</year>
<volume>16</volume>
<fpage>358</fpage>
<pub-id pub-id-type="doi">10.1038/nrn3880</pub-id>
<pub-id pub-id-type="pmid">25991443</pub-id>
</element-citation>
</ref>
<ref id="B14-cells-08-00242">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rüb</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tredici</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>Vulnerability of cortical neurons to Alzheimer’s and Parkinson’s diseases</article-title>
<source/>J. Alzheimer Dis.
          <year>2006</year>
<volume>9</volume>
<fpage>35</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2006-9S305</pub-id>
</element-citation>
</ref>
<ref id="B15-cells-08-00242">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.-H.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells</article-title>
<source/>Acta Pharmacol. Sin.
          <year>2013</year>
<volume>34</volume>
<fpage>755</fpage>
<pub-id pub-id-type="doi">10.1038/aps.2013.63</pub-id>
<pub-id pub-id-type="pmid">23685955</pub-id>
</element-citation>
</ref>
<ref id="B16-cells-08-00242">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eckman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zehr</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Prada</surname>
<given-names>C.-M.</given-names>
</name>
<name>
<surname>Perez-Tur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hutton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buee</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Harigaya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yager</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Increased amyloid-β42 (43) in brains of mice expressing mutant presenilin 1</article-title>
<source/>Nature
          <year>1996</year>
<volume>383</volume>
<fpage>710</fpage>
<pub-id pub-id-type="doi">10.1038/383710a0</pub-id>
<pub-id pub-id-type="pmid">8878479</pub-id>
</element-citation>
</ref>
<ref id="B17-cells-08-00242">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nilsen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eckman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Harigaya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Younkin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice</article-title>
<source/>Science
          <year>1996</year>
<volume>274</volume>
<fpage>99</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1126/science.274.5284.99</pub-id>
<pub-id pub-id-type="pmid">8810256</pub-id>
</element-citation>
</ref>
<ref id="B18-cells-08-00242">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sturchler-Pierrat</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Abramowski</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Duke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wiederhold</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Mistl</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rothacher</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ledermann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bürki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paganetti</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1997</year>
<volume>94</volume>
<fpage>13287</fpage>
<lpage>13292</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.24.13287</pub-id>
<pub-id pub-id-type="pmid">9371838</pub-id>
</element-citation>
</ref>
<ref id="B19-cells-08-00242">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cedazo-Minguez</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Successful therapies for Alzheimer’s disease: Why so many in animal models and none in humans?</article-title>
<source/>Front. Pharmacol.
          <year>2014</year>
<volume>5</volume>
<fpage>146</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2014.00146</pub-id>
<pub-id pub-id-type="pmid">25009496</pub-id>
</element-citation>
</ref>
<ref id="B20-cells-08-00242">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nam</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>D.-H.</given-names>
</name>
<name>
<surname>Joo</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>Adult human neural stem cell therapeutics: Current developmental status and prospect</article-title>
<source/>World J. Stem Cells
          <year>2015</year>
<volume>7</volume>
<fpage>126</fpage>
<pub-id pub-id-type="doi">10.4252/wjsc.v7.i1.126</pub-id>
<pub-id pub-id-type="pmid">25621112</pub-id>
</element-citation>
</ref>
<ref id="B21-cells-08-00242">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakel</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Svendsen</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Using human neural stem cells to model neurological disease</article-title>
<source/>Nat. Rev. Genet.
          <year>2004</year>
<volume>5</volume>
<fpage>136</fpage>
<pub-id pub-id-type="doi">10.1038/nrg1268</pub-id>
<pub-id pub-id-type="pmid">14735124</pub-id>
</element-citation>
</ref>
<ref id="B22-cells-08-00242">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Hebisch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sliwinski</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Avanzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hooli</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Asselin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Muffat</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A three-dimensional human neural cell culture model of Alzheimer’s disease</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>274</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1038/nature13800</pub-id>
<pub-id pub-id-type="pmid">25307057</pub-id>
</element-citation>
</ref>
<ref id="B23-cells-08-00242">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narazaki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Uosaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Teranishi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells</article-title>
<source/>Circulation
          <year>2008</year>
<volume>118</volume>
<fpage>498</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.769562</pub-id>
<pub-id pub-id-type="pmid">18625891</pub-id>
</element-citation>
</ref>
<ref id="B24-cells-08-00242">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jarray</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nassor</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guyot</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Cottin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rontard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mikol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mabondzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Deslys</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Small-molecule induction of Abeta-42 peptide production in human cerebral organoids to model Alzheimer’s disease associated phenotypes</article-title>
<source/>PLoS ONE
          <year>2018</year>
<volume>13</volume>
<elocation-id>e0209150</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0209150</pub-id>
<pub-id pub-id-type="pmid">30557391</pub-id>
</element-citation>
</ref>
<ref id="B25-cells-08-00242">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ataeijannati</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Head-Gordon</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Poo</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>D.V.</given-names>
</name>
</person-group>
<article-title>Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: A model system to study neurotoxicity in Alzheimer’s disease</article-title>
<source/>Neurobiol. Dis.
          <year>2014</year>
<volume>62</volume>
<fpage>62</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.09.005</pub-id>
<pub-id pub-id-type="pmid">24055772</pub-id>
</element-citation>
</ref>
<ref id="B26-cells-08-00242">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bejoy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Neural patterning of human induced pluripotent stem cells in 3-D cultures for studying biomolecule-directed differential cellular responses</article-title>
<source/>Acta Biomater.
          <year>2016</year>
<volume>42</volume>
<fpage>114</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/j.actbio.2016.06.027</pub-id>
<pub-id pub-id-type="pmid">27345135</pub-id>
</element-citation>
</ref>
<ref id="B27-cells-08-00242">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tamboli</surname>
<given-names>I.Y.</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wunderlich</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ladewig</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stuber</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Esselmann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wiltfang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brustle</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of gamma-secretase activity in endogenous amyloid-beta generation</article-title>
<source/>Am. J. Pathol.
          <year>2012</year>
<volume>180</volume>
<fpage>2404</fpage>
<lpage>2416</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.012</pub-id>
<pub-id pub-id-type="pmid">22510327</pub-id>
</element-citation>
</ref>
<ref id="B28-cells-08-00242">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodruff</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Buen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gore</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kinaga</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>L.S.</given-names>
</name>
</person-group>
<article-title>The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells</article-title>
<source/>Cell Rep.
          <year>2013</year>
<volume>5</volume>
<fpage>974</fpage>
<lpage>985</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2013.10.018</pub-id>
<pub-id pub-id-type="pmid">24239350</pub-id>
</element-citation>
</ref>
<ref id="B29-cells-08-00242">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wernig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion</article-title>
<source/>Cell
          <year>2017</year>
<volume>168</volume>
<fpage>427</fpage>
<lpage>441.e421</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.12.044</pub-id>
<pub-id pub-id-type="pmid">28111074</pub-id>
</element-citation>
</ref>
<ref id="B30-cells-08-00242">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wetzel</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dreau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>D’Avanzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Tanzi</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease</article-title>
<source/>Nat. Neurosci.
          <year>2018</year>
<volume>21</volume>
<fpage>941</fpage>
<lpage>951</lpage>
<pub-id pub-id-type="doi">10.1038/s41593-018-0175-4</pub-id>
<pub-id pub-id-type="pmid">29950669</pub-id>
</element-citation>
</ref>
<ref id="B31-cells-08-00242">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wicklund</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Leao</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Stromberg</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Mousavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hovatta</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nordberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marutle</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Beta-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e15600</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0015600</pub-id>
<pub-id pub-id-type="pmid">21179413</pub-id>
</element-citation>
</ref>
<ref id="B32-cells-08-00242">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yahata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kitaoka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Asaka</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hioki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saido</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Nakahata</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-Abeta drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer’s disease</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e25788</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0025788</pub-id>
<pub-id pub-id-type="pmid">21984949</pub-id>
</element-citation>
</ref>
<ref id="B33-cells-08-00242">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stuber</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Poppe</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Doerr</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ladewig</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brustle</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Embryonic stem cell-based modeling of tau pathology in human neurons</article-title>
<source/>Am. J. Pathol.
          <year>2013</year>
<volume>182</volume>
<fpage>1769</fpage>
<lpage>1779</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2013.01.043</pub-id>
<pub-id pub-id-type="pmid">23499461</pub-id>
</element-citation>
</ref>
<ref id="B34-cells-08-00242">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Akamatsu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nihei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshizaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Modeling familial Alzheimer’s disease with induced pluripotent stem cells</article-title>
<source/>Hum. Mol. Genet.
          <year>2011</year>
<volume>20</volume>
<fpage>4530</fpage>
<lpage>4539</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr394</pub-id>
<pub-id pub-id-type="pmid">21900357</pub-id>
</element-citation>
</ref>
<ref id="B35-cells-08-00242">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>MacLean</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Orkin</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Livesey</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome</article-title>
<source/>Sci. Transl. Med.
          <year>2012</year>
<volume>4</volume>
<fpage>124ra29</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3003771</pub-id>
</element-citation>
</ref>
<ref id="B36-cells-08-00242">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Israel</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Bardy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reyna</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hefferan</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Van Gorp</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nazor</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Boscolo</surname>
<given-names>F.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells</article-title>
<source/>Nature
          <year>2012</year>
<volume>482</volume>
<fpage>216</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1038/nature10821</pub-id>
<pub-id pub-id-type="pmid">22278060</pub-id>
</element-citation>
</ref>
<ref id="B37-cells-08-00242">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsukita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kutoku</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ohsawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sunada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Egawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yahata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Okita</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness</article-title>
<source/>Cell Stem Cell
          <year>2013</year>
<volume>12</volume>
<fpage>487</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2013.01.009</pub-id>
<pub-id pub-id-type="pmid">23434393</pub-id>
</element-citation>
</ref>
<ref id="B38-cells-08-00242">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stuber</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wunderlich</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ladewig</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kesavan</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Vandenberghe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vandenbulcke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>van Damme</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brustle</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based gamma-secretase modulation</article-title>
<source/>Stem Cell Rep.
          <year>2013</year>
<volume>1</volume>
<fpage>491</fpage>
<lpage>498</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2013.10.011</pub-id>
<pub-id pub-id-type="pmid">24371804</pub-id>
</element-citation>
</ref>
<ref id="B39-cells-08-00242">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sproul</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pre</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Nestor</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Navarro-Sobrino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santa-Maria</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aubry</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>J.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization and molecular profiling of PSEN1 familial Alzheimer’s disease iPSC-derived neural progenitors</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e84547</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0084547</pub-id>
<pub-id pub-id-type="pmid">24416243</pub-id>
</element-citation>
</ref>
<ref id="B40-cells-08-00242">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahairaki</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Burridge</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>C.C.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Asnaghi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induced pluripotent stem cells from familial Alzheimer’s disease patients differentiate into mature neurons with amyloidogenic properties</article-title>
<source/>Stem Cells Dev.
          <year>2014</year>
<volume>23</volume>
<fpage>2996</fpage>
<lpage>3010</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2013.0511</pub-id>
<pub-id pub-id-type="pmid">25027006</pub-id>
</element-citation>
</ref>
<ref id="B41-cells-08-00242">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Bhattacharyya</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Belmadani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death</article-title>
<source/>Mol. Neurodegen.
          <year>2014</year>
<volume>9</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1326-9-3</pub-id>
</element-citation>
</ref>
<ref id="B42-cells-08-00242">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muratore</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Srikanth</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Young-Pearse</surname>
<given-names>T.L.</given-names>
</name>
</person-group>
<article-title>The familial Alzheimer’s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons</article-title>
<source/>Human. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>3523</fpage>
<lpage>3536</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu064</pub-id>
<pub-id pub-id-type="pmid">24524897</pub-id>
</element-citation>
</ref>
<ref id="B43-cells-08-00242">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Waltz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Woodruff</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Israel</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sarsoza</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tanzi</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Ringman</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of potent gamma-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers</article-title>
<source/>JAMA Neurol.
          <year>2014</year>
<volume>71</volume>
<fpage>1481</fpage>
<lpage>1489</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2014.2482</pub-id>
<pub-id pub-id-type="pmid">25285942</pub-id>
</element-citation>
</ref>
<ref id="B44-cells-08-00242">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Nakauchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Schuchman</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer’s disease</article-title>
<source/>J. Exp. Med.
          <year>2014</year>
<volume>211</volume>
<fpage>1551</fpage>
<lpage>1570</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20132451</pub-id>
<pub-id pub-id-type="pmid">25049335</pub-id>
</element-citation>
</ref>
<ref id="B45-cells-08-00242">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Boulanger-Weill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Woodruff</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Buen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Revilla</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Israel</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Edland</surname>
<given-names>S.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Elucidating molecular phenotypes caused by the SORL1 Alzheimer’s disease genetic risk factor using human induced pluripotent stem cells</article-title>
<source/>Cell Stem Cell
          <year>2015</year>
<volume>16</volume>
<fpage>373</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2015.02.004</pub-id>
<pub-id pub-id-type="pmid">25772071</pub-id>
</element-citation>
</ref>
<ref id="B46-cells-08-00242">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Portelius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Saurat</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>McGlade</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>APP metabolism regulates tau proteostasis in human cerebral cortex neurons</article-title>
<source/>Cell Rep.
          <year>2015</year>
<volume>11</volume>
<fpage>689</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.068</pub-id>
<pub-id pub-id-type="pmid">25921538</pub-id>
</element-citation>
</ref>
<ref id="B47-cells-08-00242">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hossini</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Megges</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prigione</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lichtner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Toliat</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Wruck</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Schroter</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nuernberg</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kroll</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Makrantonaki</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s disease donor as a model for investigating AD-associated gene regulatory networks</article-title>
<source/>BMC Genom.
          <year>2015</year>
<volume>16</volume>
<elocation-id>84</elocation-id>
</element-citation>
</ref>
<ref id="B48-cells-08-00242">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armijo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shahnawaz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Increased susceptibility to Abeta toxicity in neuronal cultures derived from familial Alzheimer’s disease (PSEN1-A246E) induced pluripotent stem cells</article-title>
<source/>Neurosci. Lett.
          <year>2017</year>
<volume>639</volume>
<fpage>74</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2016.12.060</pub-id>
<pub-id pub-id-type="pmid">28034781</pub-id>
</element-citation>
</ref>
<ref id="B49-cells-08-00242">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Lum</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vallotton</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>31450</fpage>
<pub-id pub-id-type="doi">10.1038/srep31450</pub-id>
<pub-id pub-id-type="pmid">27514990</pub-id>
</element-citation>
</ref>
<ref id="B50-cells-08-00242">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Muratore</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Gierahn</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Srikanth</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Jager</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Young-Pearse</surname>
<given-names>T.L.</given-names>
</name>
</person-group>
<article-title>Single-Cell Detection of Secreted Aβ and sAPPα from Human IPSC-Derived Neurons and Astrocytes</article-title>
<source/>J. Neurosci.
          <year>2016</year>
<volume>36</volume>
<fpage>1730</fpage>
<lpage>1746</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2735-15.2016</pub-id>
<pub-id pub-id-type="pmid">26843653</pub-id>
</element-citation>
</ref>
<ref id="B51-cells-08-00242">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Velazquez Sanchez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morin</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hanlon</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Three Dimensional Human Neuro-Spheroid Model of Alzheimer’s Disease Based on Differentiated Induced Pluripotent Stem Cells</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0163072</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0163072</pub-id>
<pub-id pub-id-type="pmid">27684569</pub-id>
</element-citation>
</ref>
<ref id="B52-cells-08-00242">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raja</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Mungenast</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Abdurrob</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>L.H.</given-names>
</name>
</person-group>
<article-title>Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer’s Disease Phenotypes</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<elocation-id>e0161969</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0161969</pub-id>
<pub-id pub-id-type="pmid">27622770</pub-id>
</element-citation>
</ref>
<ref id="B53-cells-08-00242">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Atkinson-Dell</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Verkhratsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohamet</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Aberrant iPSC-derived human astrocytes in Alzheimer’s disease</article-title>
<source/>Cell Death Dis.
          <year>2017</year>
<volume>8</volume>
<fpage>e2696</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2017.89</pub-id>
<pub-id pub-id-type="pmid">28333144</pub-id>
</element-citation>
</ref>
<ref id="B54-cells-08-00242">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muratore</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Lagomarsino</surname>
<given-names>V.N.</given-names>
</name>
<name>
<surname>Pearse</surname>
<given-names>R.V.</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Rice</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Negri</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cell-type Dependent Alzheimer’s Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability</article-title>
<source/>Stem Cell Rep.
          <year>2017</year>
<volume>9</volume>
<fpage>1868</fpage>
<lpage>1884</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.10.015</pub-id>
<pub-id pub-id-type="pmid">29153990</pub-id>
</element-citation>
</ref>
<ref id="B55-cells-08-00242">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kondo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Funayama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsukita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Woltjen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid beta Combination for Alzheimer’s Disease</article-title>
<source/>Cell Rep.
          <year>2017</year>
<volume>21</volume>
<fpage>2304</fpage>
<lpage>2312</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2017.10.109</pub-id>
<pub-id pub-id-type="pmid">29166618</pub-id>
</element-citation>
</ref>
<ref id="B56-cells-08-00242">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochalek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mihalik</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Avci</surname>
<given-names>H.X.</given-names>
</name>
<name>
<surname>Chandrasekaran</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Teglasi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bock</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Tancos</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Molnar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Laszlo</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation</article-title>
<source/>Alzheimers Res. Ther.
          <year>2017</year>
<volume>9</volume>
<fpage>90</fpage>
<pub-id pub-id-type="doi">10.1186/s13195-017-0317-z</pub-id>
<pub-id pub-id-type="pmid">29191219</pub-id>
</element-citation>
</ref>
<ref id="B57-cells-08-00242">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oksanen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Naumenko</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Puttonen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gubert Olive</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shakirzyanova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leskela</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sarajarvi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Viitanen</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer’s Disease</article-title>
<source/>Stem Cell Rep.
          <year>2017</year>
<volume>9</volume>
<fpage>1885</fpage>
<lpage>1897</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.10.016</pub-id>
</element-citation>
</ref>
<ref id="B58-cells-08-00242">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>N.W.</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Klyubin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>O’Malley</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Livesey</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Rowan</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Extracellular Forms of Abeta and Tau from iPSC Models of Alzheimer’s Disease Disrupt Synaptic Plasticity</article-title>
<source/>Cell Rep.
          <year>2018</year>
<volume>23</volume>
<fpage>1932</fpage>
<lpage>1938</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.040</pub-id>
<pub-id pub-id-type="pmid">29768194</pub-id>
</element-citation>
</ref>
<ref id="B59-cells-08-00242">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bejoy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kanekiyo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Modelling neurodegenerative microenvironment using cortical organoids derived from human stem cells</article-title>
<source/>Tissue Eng. Part A
          <year>2018</year>
<volume>24</volume>
<fpage>1125</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="doi">10.1089/ten.tea.2017.0423</pub-id>
<pub-id pub-id-type="pmid">29361890</pub-id>
</element-citation>
</ref>
<ref id="B60-cells-08-00242">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Armijo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bravo-Alegria</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Becerra-Calixto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Modeling amyloid beta and tau pathology in human cerebral organoids</article-title>
<source/>Mol. Psychiatry
          <year>2018</year>
<volume>23</volume>
<fpage>2363</fpage>
<lpage>2374</lpage>
<pub-id pub-id-type="doi">10.1038/s41380-018-0229-8</pub-id>
<pub-id pub-id-type="pmid">30171212</pub-id>
</element-citation>
</ref>
<ref id="B61-cells-08-00242">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Penney</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cam</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Gjoneska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Raja</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease Phenotypes in Human iPSC-Derived Brain Cell Types</article-title>
<source/>Neuron
          <year>2018</year>
<volume>98</volume>
<fpage>1141</fpage>
<lpage>1154</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2018.05.008</pub-id>
<pub-id pub-id-type="pmid">29861287</pub-id>
</element-citation>
</ref>
<ref id="B62-cells-08-00242">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Moo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hanlon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Common proteomic profiles of induced pluripotent stem cell-derived three-dimensional neurons and brain tissue from Alzheimer patients</article-title>
<source/>J. Proteom.
          <year>2018</year>
<volume>182</volume>
<fpage>21</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.jprot.2018.04.032</pub-id>
<pub-id pub-id-type="pmid">29709615</pub-id>
</element-citation>
</ref>
<ref id="B63-cells-08-00242">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birnbaum</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Wanner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gietl</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Saake</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kundig</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Hock</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nitsch</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Tackenberg</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-beta and tau pathology in iPSC-derived neurons from sporadic Alzheimer’s disease patients</article-title>
<source/>Stem Cell Res.
          <year>2018</year>
<volume>27</volume>
<fpage>121</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.scr.2018.01.019</pub-id>
<pub-id pub-id-type="pmid">29414602</pub-id>
</element-citation>
</ref>
<ref id="B64-cells-08-00242">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Frankowski</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Petsko</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>L.S.B.</given-names>
</name>
</person-group>
<article-title>Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein</article-title>
<source/>Stem Cell Rep.
          <year>2018</year>
<volume>10</volume>
<fpage>1046</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2018.01.031</pub-id>
<pub-id pub-id-type="pmid">29503090</pub-id>
</element-citation>
</ref>
<ref id="B65-cells-08-00242">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ovchinnikov</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Korn</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Wolvetang</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>The Impact of APP on Alzheimer-like Pathogenesis and Gene Expression in Down Syndrome iPSC-Derived Neurons</article-title>
<source/>Stem Cell Rep.
          <year>2018</year>
<volume>11</volume>
<fpage>32</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2018.05.004</pub-id>
<pub-id pub-id-type="pmid">29861166</pub-id>
</element-citation>
</ref>
<ref id="B66-cells-08-00242">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Najm</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Balestra</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>Z.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector</article-title>
<source/>Nat. Med.
          <year>2018</year>
<volume>24</volume>
<fpage>647</fpage>
<lpage>657</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-018-0004-z</pub-id>
<pub-id pub-id-type="pmid">29632371</pub-id>
</element-citation>
</ref>
<ref id="B67-cells-08-00242">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ducy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Karsenty</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Franceschi</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Ascorbic acid-dependent activation of the osteocalcin promoter in MC3T3-E1 preosteoblasts: Requirement for collagen matrix synthesis and the presence of an intact OSE2 sequence</article-title>
<source/>Mol. Endocrinol.
          <year>1997</year>
<volume>11</volume>
<fpage>1103</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="doi">10.1210/mend.11.8.9955</pub-id>
<pub-id pub-id-type="pmid">9212058</pub-id>
</element-citation>
</ref>
<ref id="B68-cells-08-00242">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Direct Conversion of Normal and Alzheimer’s Disease Human Fibroblasts into Neuronal Cells by Small Molecules</article-title>
<source/>Cell Stem Cell
          <year>2015</year>
<volume>17</volume>
<fpage>204</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2015.07.006</pub-id>
<pub-id pub-id-type="pmid">26253202</pub-id>
</element-citation>
</ref>
<ref id="B69-cells-08-00242">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espuny-Camacho</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Arranz</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Fiers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Snellinx</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Munck</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonnefont</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lambot</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Corthout</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Omodho</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hallmarks of Alzheimer’s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain</article-title>
<source/>Neuron
          <year>2017</year>
<volume>93</volume>
<fpage>1066</fpage>
<lpage>1081.e1068</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.001</pub-id>
<pub-id pub-id-type="pmid">28238547</pub-id>
</element-citation>
</ref>
<ref id="B70-cells-08-00242">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meyer-Franke</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening</article-title>
<source/>Stem Cell Rep.
          <year>2017</year>
<volume>9</volume>
<fpage>1221</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2017.08.019</pub-id>
</element-citation>
</ref>
<ref id="B71-cells-08-00242">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harasta</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Ittner</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons</article-title>
<source/>Adv. Neurobiol.
          <year>2017</year>
<volume>15</volume>
<fpage>3</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">28674976</pub-id>
</element-citation>
</ref>
<ref id="B72-cells-08-00242">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jorfi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D’Avanzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tanzi</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Irimia</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>2450</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-20436-8</pub-id>
<pub-id pub-id-type="pmid">29402979</pub-id>
</element-citation>
</ref>
<ref id="B73-cells-08-00242">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Reyna</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Woodruff</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Probing the secrets of Alzheimer’s disease using human-induced pluripotent stem cell technology</article-title>
<source/>Neurotherapeutics
          <year>2015</year>
<volume>12</volume>
<fpage>121</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-014-0326-6</pub-id>
<pub-id pub-id-type="pmid">25534395</pub-id>
</element-citation>
</ref>
<ref id="B74-cells-08-00242">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ashton</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rode</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>D.V.</given-names>
</name>
</person-group>
<article-title>The effect of multivalent Sonic hedgehog on differentiation of human embryonic stem cells into dopaminergic and GABAergic neurons</article-title>
<source/>Biomaterials
          <year>2014</year>
<volume>35</volume>
<fpage>941</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.10.025</pub-id>
<pub-id pub-id-type="pmid">24172856</pub-id>
</element-citation>
</ref>
<ref id="B75-cells-08-00242">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>Z.-W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.-L.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.-C.</given-names>
</name>
</person-group>
<article-title>Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>6626</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms7626</pub-id>
<pub-id pub-id-type="pmid">25806427</pub-id>
</element-citation>
</ref>
<ref id="B76-cells-08-00242">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hattori</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Cerebral organoids model human brain development and microcephaly</article-title>
<source/>Mov. Disord.
          <year>2014</year>
<volume>29</volume>
<fpage>185</fpage>
<pub-id pub-id-type="doi">10.1002/mds.25740</pub-id>
<pub-id pub-id-type="pmid">24375826</pub-id>
</element-citation>
</ref>
<ref id="B77-cells-08-00242">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paşca</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Sloan</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Makinson</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>O’rourke</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture</article-title>
<source/>Nat. Methods
          <year>2015</year>
<volume>12</volume>
<fpage>671</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.3415</pub-id>
<pub-id pub-id-type="pmid">26005811</pub-id>
</element-citation>
</ref>
<ref id="B78-cells-08-00242">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martins-Taylor</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kronenberg</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Lichtler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.-X.</given-names>
</name>
</person-group>
<article-title>Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e11853</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0011853</pub-id>
<pub-id pub-id-type="pmid">20686615</pub-id>
</element-citation>
</ref>
<ref id="B79-cells-08-00242">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imaizumi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sone</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ibata</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujimori</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yuzaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akamatsu</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Controlling the Regional Identity of hPSC-Derived Neurons to Uncover Neuronal Subtype Specificity of Neurological Disease Phenotypes</article-title>
<source/>Stem Cell Rep.
          <year>2015</year>
<volume>5</volume>
<fpage>1010</fpage>
<lpage>1022</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2015.10.005</pub-id>
<pub-id pub-id-type="pmid">26549851</pub-id>
</element-citation>
</ref>
<ref id="B80-cells-08-00242">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Livesey</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks</article-title>
<source/>Nat. Protoc.
          <year>2012</year>
<volume>7</volume>
<fpage>1836</fpage>
<pub-id pub-id-type="doi">10.1038/nprot.2012.116</pub-id>
<pub-id pub-id-type="pmid">22976355</pub-id>
</element-citation>
</ref>
<ref id="B81-cells-08-00242">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Vanderhaeghen</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Is this a brain which I see before me? Modeling human neural development with pluripotent stem cells</article-title>
<source/>Development
          <year>2015</year>
<volume>142</volume>
<fpage>3138</fpage>
<lpage>3150</lpage>
<pub-id pub-id-type="doi">10.1242/dev.120568</pub-id>
<pub-id pub-id-type="pmid">26395142</pub-id>
</element-citation>
</ref>
<ref id="B82-cells-08-00242">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pham</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Cary</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nolta</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Waldau</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Generation of human vascularized brain organoids</article-title>
<source/>Neuroreport
          <year>2018</year>
<volume>29</volume>
<fpage>588</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1097/WNR.0000000000001014</pub-id>
<pub-id pub-id-type="pmid">29570159</pub-id>
</element-citation>
</ref>
<ref id="B83-cells-08-00242">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansour</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Goncalves</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Bloyd</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Quang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Parylak</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>F.H.</given-names>
</name>
</person-group>
<article-title>An in vivo model of functional and vascularized human brain organoids</article-title>
<source/>Nat. Biotechnol.
          <year>2018</year>
<volume>36</volume>
<fpage>432</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.4127</pub-id>
<pub-id pub-id-type="pmid">29658944</pub-id>
</element-citation>
</ref>
<ref id="B84-cells-08-00242">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wimmer</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Leopoldi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aichinger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wick</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hantusch</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Novatchkova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taubenschmid</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hammerle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esk</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bagley</surname>
<given-names>J.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human blood vessel organoids as a model of diabetic vasculopathy</article-title>
<source/>Nature
          <year>2019</year>
<volume>565</volume>
<fpage>505</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-018-0858-8</pub-id>
<pub-id pub-id-type="pmid">30651639</pub-id>
</element-citation>
</ref>
<ref id="B85-cells-08-00242">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lou</surname>
<given-names>Y.R.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>A.W.</given-names>
</name>
</person-group>
<article-title>Next generation organoids for biomedical research and applications</article-title>
<source/>Biotechnol. Adv.
          <year>2018</year>
<volume>36</volume>
<fpage>132</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1016/j.biotechadv.2017.10.005</pub-id>
<pub-id pub-id-type="pmid">29056474</pub-id>
</element-citation>
</ref>
<ref id="B86-cells-08-00242">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatehullah</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Organoids as an in vitro model of human development and disease</article-title>
<source/>Nat. Cell Biol.
          <year>2016</year>
<volume>18</volume>
<fpage>246</fpage>
<pub-id pub-id-type="doi">10.1038/ncb3312</pub-id>
<pub-id pub-id-type="pmid">26911908</pub-id>
</element-citation>
</ref>
<ref id="B87-cells-08-00242">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>In vitro organogenesis from pluripotent stem cells</article-title>
<source/>Organogenesis
          <year>2014</year>
<volume>10</volume>
<fpage>159</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.4161/org.28918</pub-id>
<pub-id pub-id-type="pmid">24762764</pub-id>
</element-citation>
</ref>
<ref id="B88-cells-08-00242">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mead</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Safaee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Karp</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Engineering stem cell organoids</article-title>
<source/>Cell Stem Cell
          <year>2016</year>
<volume>18</volume>
<fpage>25</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2015.12.005</pub-id>
<pub-id pub-id-type="pmid">26748754</pub-id>
</element-citation>
</ref>
<ref id="B89-cells-08-00242">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancaster</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Knoblich</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Organogenesis in a dish: Modeling development and disease using organoid technologies</article-title>
<source/>Science
          <year>2014</year>
<volume>345</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1126/science.1247125</pub-id>
</element-citation>
</ref>
<ref id="B90-cells-08-00242">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passier</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Orlova</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Complex tissue and disease modeling using hiPSCs</article-title>
<source/>Cell Stem Cell
          <year>2016</year>
<volume>18</volume>
<fpage>309</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2016.02.011</pub-id>
<pub-id pub-id-type="pmid">26942851</pub-id>
</element-citation>
</ref>
<ref id="B91-cells-08-00242">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S.-C.</given-names>
</name>
<name>
<surname>Wernig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Brüstle</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>In vitro differentiation of transplantable neural precursors from human embryonic stem cells</article-title>
<source/>Nat. Biotechnol.
          <year>2001</year>
<volume>19</volume>
<fpage>1129</fpage>
<pub-id pub-id-type="doi">10.1038/nbt1201-1129</pub-id>
<pub-id pub-id-type="pmid">11731781</pub-id>
</element-citation>
</ref>
<ref id="B92-cells-08-00242">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eiraku</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsuo-Takasaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yonemura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wataya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muguruma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasail</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Self-Organized Formation of Polarized Cortical Tissues from ESCs and Its Active Manipulation by Extrinsic Signals</article-title>
<source/>Cell Stem Cell
          <year>2008</year>
<volume>3</volume>
<fpage>519</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2008.09.002</pub-id>
<pub-id pub-id-type="pmid">18983967</pub-id>
</element-citation>
</ref>
<ref id="B93-cells-08-00242">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eiraku</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kawada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sakakura</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Adachi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sasai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Self-organizing optic-cup morphogenesis in three-dimensional culture</article-title>
<source/>Nature
          <year>2011</year>
<volume>472</volume>
<fpage>51</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1038/nature09941</pub-id>
<pub-id pub-id-type="pmid">21475194</pub-id>
</element-citation>
</ref>
<ref id="B94-cells-08-00242">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariani</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Simonini</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Palejev</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tomasini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Szekely</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Vaccarino</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Modeling human cortical development in vitro using induced pluripotent stem cells</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2012</year>
<volume>109</volume>
<fpage>12770</fpage>
<lpage>12775</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1202944109</pub-id>
<pub-id pub-id-type="pmid">22761314</pub-id>
</element-citation>
</ref>
<ref id="B95-cells-08-00242">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lancaster</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Renner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bicknell</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Hurles</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Homfray</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Penninger</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Knoblich</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Cerebral organoids model human brain development and microcephaly</article-title>
<source/>Nature
          <year>2013</year>
<volume>501</volume>
<fpage>373</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1038/nature12517</pub-id>
<pub-id pub-id-type="pmid">23995685</pub-id>
</element-citation>
</ref>
<ref id="B96-cells-08-00242">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Hadiono</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ogden</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hammack</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hamersky</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure</article-title>
<source/>Cell
          <year>2016</year>
<volume>165</volume>
<fpage>1238</fpage>
<lpage>1254</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.04.032</pub-id>
<pub-id pub-id-type="pmid">27118425</pub-id>
</element-citation>
</ref>
<ref id="B97-cells-08-00242">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariani</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Abyzov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Provini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tomasini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Amenduni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Szekely</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Palejev</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FOXG1-dependent dysregulation of GABA/Glutamate neuron differentiation in Autism Spectrum Disorders</article-title>
<source/>Cell
          <year>2015</year>
<volume>162</volume>
<fpage>375</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.06.034</pub-id>
<pub-id pub-id-type="pmid">26186191</pub-id>
</element-citation>
</ref>
<ref id="B98-cells-08-00242">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birey</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Makinson</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Metzler</surname>
<given-names>K.R.C.</given-names>
</name>
<name>
<surname>Panagiotakos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thom</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assembly of functionally integrated human forebrain spheroids</article-title>
<source/>Nature
          <year>2017</year>
<volume>545</volume>
<fpage>54</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1038/nature22330</pub-id>
<pub-id pub-id-type="pmid">28445465</pub-id>
</element-citation>
</ref>
<ref id="B99-cells-08-00242">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Repic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kavirayani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Burkard</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bagley</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Krauditsch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Knoblich</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Genetically engineered cerebral organoids model brain tumor formation</article-title>
<source/>Nat. Methods
          <year>2018</year>
<volume>15</volume>
<fpage>631</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1038/s41592-018-0070-7</pub-id>
<pub-id pub-id-type="pmid">30038414</pub-id>
</element-citation>
</ref>
<ref id="B100-cells-08-00242">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pao</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Shokhirev</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>I.M.</given-names>
</name>
</person-group>
<article-title>Glioblastoma Model Using Human Cerebral Organoids</article-title>
<source/>Cell Rep.
          <year>2018</year>
<volume>23</volume>
<fpage>1220</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.105</pub-id>
<pub-id pub-id-type="pmid">29694897</pub-id>
</element-citation>
</ref>
<ref id="B101-cells-08-00242">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Pasca</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Building Models of Brain Disorders with Three-Dimensional Organoids</article-title>
<source/>Neuron
          <year>2018</year>
<volume>100</volume>
<fpage>389</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2018.10.007</pub-id>
<pub-id pub-id-type="pmid">30359604</pub-id>
</element-citation>
</ref>
<ref id="B102-cells-08-00242">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Madinya</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Derivation of cortical spheroids from human induced pluripotent stem cells in a suspension bioreactor</article-title>
<source/>Tissue Eng. Part A
          <year>2018</year>
<volume>24</volume>
<fpage>418</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1089/ten.tea.2016.0400</pub-id>
<pub-id pub-id-type="pmid">28825364</pub-id>
</element-citation>
</ref>
<ref id="B103-cells-08-00242">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Noor</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Harel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fleischer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Adadi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Shabat</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shapira</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants</article-title>
<source/>Adv. Mater.
          <year>2019</year>
<volume>31</volume>
<fpage>e1803895</fpage>
<pub-id pub-id-type="doi">10.1002/adma.201803895</pub-id>
<pub-id pub-id-type="pmid">30406960</pub-id>
</element-citation>
</ref>
<ref id="B104-cells-08-00242">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sart</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lochner</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Crosslinking of extracellular matrix scaffolds derived from pluripotent stem cell aggregates modulates neural differentiation</article-title>
<source/>Acta Biomater.
          <year>2016</year>
<volume>30</volume>
<fpage>222</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1016/j.actbio.2015.11.016</pub-id>
<pub-id pub-id-type="pmid">26577988</pub-id>
</element-citation>
</ref>
<ref id="B105-cells-08-00242">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kokovay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>S.-M.</given-names>
</name>
<name>
<surname>Goderie</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Roysam</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Temple</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Adult SVZ stem cells lie in a vascular niche: A quantitative analysis of niche cell-cell interactions</article-title>
<source/>Cell Stem Cell
          <year>2008</year>
<volume>3</volume>
<fpage>289</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2008.07.026</pub-id>
<pub-id pub-id-type="pmid">18786416</pub-id>
</element-citation>
</ref>
<ref id="B106-cells-08-00242">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Bosco</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Bundy</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Nowakowski</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>Q.-X.A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Differential effects of acellular embryonic matrices on pluripotent stem cell expansion and neural differentiation</article-title>
<source/>Biomaterials
          <year>2015</year>
<volume>73</volume>
<fpage>231</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.09.020</pub-id>
<pub-id pub-id-type="pmid">26410789</pub-id>
</element-citation>
</ref>
<ref id="B107-cells-08-00242">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bejoy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bijonowski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>Q.X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Differential effects of heparin and hyaluronic acid on neural patterning of human induced pluripotent stem cells</article-title>
<source/>ACS Biomater. Sci. Eng.
          <year>2018</year>
<volume>4</volume>
<fpage>4354</fpage>
<lpage>4366</lpage>
<pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b01142</pub-id>
</element-citation>
</ref>
<ref id="B108-cells-08-00242">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Pluripotent stem cell expansion and neural differentiation in 3-D scaffolds of tunable Poisson’s ratio</article-title>
<source/>Acta Biomater.
          <year>2017</year>
<volume>49</volume>
<fpage>192</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1016/j.actbio.2016.11.025</pub-id>
<pub-id pub-id-type="pmid">27845272</pub-id>
</element-citation>
</ref>
<ref id="B109-cells-08-00242">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Discher</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Mooney</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Zandstra</surname>
<given-names>P.W.</given-names>
</name>
</person-group>
<article-title>Growth factors, matrices, and forces combine and control stem cells</article-title>
<source/>Science
          <year>2009</year>
<volume>324</volume>
<fpage>1673</fpage>
<lpage>1677</lpage>
<pub-id pub-id-type="doi">10.1126/science.1171643</pub-id>
<pub-id pub-id-type="pmid">19556500</pub-id>
</element-citation>
</ref>
<ref id="B110-cells-08-00242">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engler</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Discher</surname>
<given-names>D.E.</given-names>
</name>
</person-group>
<article-title>Matrix elasticity directs stem cell lineage specification</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>677</fpage>
<lpage>689</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.06.044</pub-id>
<pub-id pub-id-type="pmid">16923388</pub-id>
</element-citation>
</ref>
<ref id="B111-cells-08-00242">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saha</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Keung</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>K.E.</given-names>
</name>
</person-group>
<article-title>Substrate modulus directs neural stem cell behavior</article-title>
<source/>Biophys. J.
          <year>2008</year>
<volume>95</volume>
<fpage>4426</fpage>
<lpage>4438</lpage>
<pub-id pub-id-type="doi">10.1529/biophysj.108.132217</pub-id>
<pub-id pub-id-type="pmid">18658232</pub-id>
</element-citation>
</ref>
<ref id="B112-cells-08-00242">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leipzig</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Shoichet</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>The effect of substrate stiffness on adult neural stem cell behavior</article-title>
<source/>Biomaterials
          <year>2009</year>
<volume>30</volume>
<fpage>6867</fpage>
<lpage>6878</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.09.002</pub-id>
<pub-id pub-id-type="pmid">19775749</pub-id>
</element-citation>
</ref>
<ref id="B113-cells-08-00242">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kothapalli</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Kamm</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>3D matrix microenvironment for targeted differentiation of embryonic stem cells into neural and glial lineages</article-title>
<source/>Biomaterials
          <year>2013</year>
<volume>34</volume>
<fpage>5995</fpage>
<lpage>6007</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.04.042</pub-id>
<pub-id pub-id-type="pmid">23694902</pub-id>
</element-citation>
</ref>
<ref id="B114-cells-08-00242">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lantoine</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grevesse</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Villers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Delhaye</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mestdagh</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Versaevel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bruyere</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Alaimo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lacour</surname>
<given-names>S.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Matrix stiffness modulates formation and activity of neuronal networks of controlled architectures</article-title>
<source/>Biomaterials
          <year>2016</year>
<volume>89</volume>
<fpage>14</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.02.041</pub-id>
<pub-id pub-id-type="pmid">26946402</pub-id>
</element-citation>
</ref>
<ref id="B115-cells-08-00242">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madl</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>LeSavage</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Dewi</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Dinh</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Stowers</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Khariton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lampe</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chaudhuri</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Enejder</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maintenance of neural progenitor cell stemness in 3D hydrogels requires matrix remodelling</article-title>
<source/>Nat. Mater.
          <year>2017</year>
<volume>16</volume>
<fpage>1233</fpage>
<lpage>1242</lpage>
<pub-id pub-id-type="doi">10.1038/nmat5020</pub-id>
<pub-id pub-id-type="pmid">29115291</pub-id>
</element-citation>
</ref>
<ref id="B116-cells-08-00242">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Janairo</surname>
<given-names>R.R.R.</given-names>
</name>
<name>
<surname>Kwong</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Matrix stiffness modulates the differentiation of neural crest stem cells in vivo</article-title>
<source/>J. Cell. Physiol.
          <year>2019</year>
<volume>234</volume>
<fpage>7569</fpage>
<lpage>7578</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.27518</pub-id>
<pub-id pub-id-type="pmid">30368818</pub-id>
</element-citation>
</ref>
<ref id="B117-cells-08-00242">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Y.Q.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.C.</given-names>
</name>
</person-group>
<article-title>Substrate stiffness affects neural network activity in an extracellular matrix proteins dependent manner</article-title>
<source/>Colloids Surf. B Biointerfaces
          <year>2018</year>
<volume>170</volume>
<fpage>729</fpage>
<lpage>735</lpage>
<pub-id pub-id-type="doi">10.1016/j.colsurfb.2018.03.042</pub-id>
<pub-id pub-id-type="pmid">30005410</pub-id>
</element-citation>
</ref>
<ref id="B118-cells-08-00242">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Toh</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Toh</surname>
<given-names>Y.C.</given-names>
</name>
</person-group>
<article-title>Substrate stiffness modulates the multipotency of human neural crest derived ectomesenchymal stem cells via CD44 mediated PDGFR signaling</article-title>
<source/>Biomaterials
          <year>2018</year>
<volume>167</volume>
<fpage>153</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.03.022</pub-id>
<pub-id pub-id-type="pmid">29571051</pub-id>
</element-citation>
</ref>
<ref id="B119-cells-08-00242">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keung</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Asuri</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>D.V.</given-names>
</name>
</person-group>
<article-title>Soft microenvironments promote the early neurogenic differentiation but not self-renewal of human pluripotent stem cells</article-title>
<source/>Integr. Biol.
          <year>2012</year>
<volume>4</volume>
<fpage>1049</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="doi">10.1039/c2ib20083j</pub-id>
</element-citation>
</ref>
<ref id="B120-cells-08-00242">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Discher</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Janmey</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.-l.</given-names>
</name>
</person-group>
<article-title>Tissue cells feel and respond to the stiffness of their substrate</article-title>
<source/>Science
          <year>2005</year>
<volume>310</volume>
<fpage>1139</fpage>
<lpage>1143</lpage>
<pub-id pub-id-type="doi">10.1126/science.1116995</pub-id>
<pub-id pub-id-type="pmid">16293750</pub-id>
</element-citation>
</ref>
<ref id="B121-cells-08-00242">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagliara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Franze</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Wylde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>R.J.M.</given-names>
</name>
<name>
<surname>Kabla</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Keyser</surname>
<given-names>U.F.</given-names>
</name>
<name>
<surname>Chalut</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Auxetic nuclei in embryonic stem cells exiting pluripotency</article-title>
<source/>Nat. Mater.
          <year>2014</year>
<volume>13</volume>
<fpage>638</fpage>
<lpage>644</lpage>
<pub-id pub-id-type="doi">10.1038/nmat3943</pub-id>
<pub-id pub-id-type="pmid">24747782</pub-id>
</element-citation>
</ref>
<ref id="B122-cells-08-00242">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Minelli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gentleman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>LaPointe</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Patankar</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Kallivretaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Substrate stiffness affects early differentiation events in embryonic stem cells</article-title>
<source/>Eur. Cells Mater.
          <year>2009</year>
<volume>18</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.22203/eCM.v018a01</pub-id>
</element-citation>
</ref>
<ref id="B123-cells-08-00242">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banerjee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashton</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>The influence of hydrogel modulus on the proliferation and differentiation of encapsulated neural stem cells</article-title>
<source/>Biomaterials
          <year>2009</year>
<volume>30</volume>
<fpage>4695</fpage>
<lpage>4699</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.05.050</pub-id>
<pub-id pub-id-type="pmid">19539367</pub-id>
</element-citation>
</ref>
<ref id="B124-cells-08-00242">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chowdhury</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Poh</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Material properties of the cell dictate stress-induced spreading and differentiation in embryonic stem cells</article-title>
<source/>Nat. Mater.
          <year>2010</year>
<volume>9</volume>
<fpage>82</fpage>
<pub-id pub-id-type="doi">10.1038/nmat2563</pub-id>
<pub-id pub-id-type="pmid">19838182</pub-id>
</element-citation>
</ref>
<ref id="B125-cells-08-00242">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Morin</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Wrighton</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Zwick</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kiessling</surname>
<given-names>L.L.</given-names>
</name>
</person-group>
<article-title>Glycosaminoglycan-binding hydrogels enable mechanical control of human pluripotent stem cell self-renewal</article-title>
<source/>ACS Nano
          <year>2012</year>
<volume>6</volume>
<fpage>10168</fpage>
<lpage>10177</lpage>
<pub-id pub-id-type="doi">10.1021/nn3039148</pub-id>
<pub-id pub-id-type="pmid">23005914</pub-id>
</element-citation>
</ref>
<ref id="B126-cells-08-00242">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoldan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Levenberg</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The influence of scaffold elasticity on germ layer specification of human embryonic stem cells</article-title>
<source/>Biomaterials
          <year>2011</year>
<volume>32</volume>
<fpage>9612</fpage>
<lpage>9621</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.09.012</pub-id>
<pub-id pub-id-type="pmid">21963156</pub-id>
</element-citation>
</ref>
<ref id="B127-cells-08-00242">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arshi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Eaimkhong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Evseenko</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stieg</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Gimzewski</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Rigid Microenvironments Promote Cardiac Differentiation Of Mouse And Human Embryonic Stem Cells</article-title>
<source/>Circ. Res.
          <year>2013</year>
<volume>113</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1088/1468-6996/14/2/025003</pub-id>
</element-citation>
</ref>
<ref id="B128-cells-08-00242">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eroshenko</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yadavalli</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>R.R.</given-names>
</name>
</person-group>
<article-title>Effect of substrate stiffness on early human embryonic stem cell differentiation</article-title>
<source/>J. Biol. Eng.
          <year>2013</year>
<volume>7</volume>
<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/1754-1611-7-7</pub-id>
<pub-id pub-id-type="pmid">23517522</pub-id>
</element-citation>
</ref>
<ref id="B129-cells-08-00242">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>V.Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rajendran</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>A.C.A.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>J.Y.</given-names>
</name>
</person-group>
<article-title>Extracellular Matrix-Mediated Differentiation of Human Embryonic Stem Cells: Differentiation to Insulin-Secreting Beta Cells</article-title>
<source/>Tissue Eng. Part A
          <year>2014</year>
<volume>20</volume>
<fpage>424</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1089/ten.tea.2013.0257</pub-id>
<pub-id pub-id-type="pmid">24020641</pub-id>
</element-citation>
</ref>
<ref id="B130-cells-08-00242">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazeltine</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Badur</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Palecek</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Temporal impact of substrate mechanics on differentiation of human embryonic stem cells to cardiomyocytes</article-title>
<source/>Acta Biomater.
          <year>2014</year>
<volume>10</volume>
<fpage>604</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="doi">10.1016/j.actbio.2013.10.033</pub-id>
<pub-id pub-id-type="pmid">24200714</pub-id>
</element-citation>
</ref>
<ref id="B131-cells-08-00242">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maldonado</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>L.Y.</given-names>
</name>
<name>
<surname>Echeverria</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ico</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujimoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The effects of electrospun substrate-mediated cell colony morphology on the self-renewal of human induced pluripotent stem cells</article-title>
<source/>Biomaterials
          <year>2015</year>
<volume>50</volume>
<fpage>10</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.01.037</pub-id>
<pub-id pub-id-type="pmid">25736491</pub-id>
</element-citation>
</ref>
<ref id="B132-cells-08-00242">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribeiro</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Rivas</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pruitt</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2015</year>
<volume>112</volume>
<fpage>12705</fpage>
<lpage>12710</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1508073112</pub-id>
<pub-id pub-id-type="pmid">26417073</pub-id>
</element-citation>
</ref>
<ref id="B133-cells-08-00242">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mittal</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tasnim</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Phan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>M.-H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Substrate Stiffness Modulates the Maturation of Human Pluripotent Stem-Cell-Derived Hepatocytes</article-title>
<source/>ACS Biomater. Sci. Eng.
          <year>2016</year>
<volume>2</volume>
<fpage>1649</fpage>
<lpage>1657</lpage>
<pub-id pub-id-type="doi">10.1021/acsbiomaterials.6b00475</pub-id>
</element-citation>
</ref>
<ref id="B134-cells-08-00242">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caiazzo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ranga</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Piersigilli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tabata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lutolf</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Defined three-dimensional microenvironments boost induction of pluripotency</article-title>
<source/>Nat. Mater.
          <year>2016</year>
<volume>15</volume>
<fpage>344</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1038/nmat4536</pub-id>
<pub-id pub-id-type="pmid">26752655</pub-id>
</element-citation>
</ref>
<ref id="B135-cells-08-00242">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Przybyla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lakins</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>V.M.</given-names>
</name>
</person-group>
<article-title>Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation</article-title>
<source/>Cell Stem Cell
          <year>2016</year>
<volume>19</volume>
<fpage>462</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2016.06.018</pub-id>
<pub-id pub-id-type="pmid">27452175</pub-id>
</element-citation>
</ref>
<ref id="B136-cells-08-00242">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Barner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Candiello</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumta</surname>
<given-names>P.N.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Capsule stiffness regulates the efficiency of pancreatic differentiation of human embryonic stem cells</article-title>
<source/>Acta Biomater.
          <year>2016</year>
<volume>35</volume>
<fpage>153</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/j.actbio.2016.02.025</pub-id>
<pub-id pub-id-type="pmid">26911881</pub-id>
</element-citation>
</ref>
<ref id="B137-cells-08-00242">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gjorevski</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Manfrin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bragina</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Ordonez-Moran</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lutolf</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Designer matrices for intestinal stem cell and organoid culture</article-title>
<source/>Nature
          <year>2016</year>
<volume>539</volume>
<fpage>560</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1038/nature20168</pub-id>
<pub-id pub-id-type="pmid">27851739</pub-id>
</element-citation>
</ref>
<ref id="B138-cells-08-00242">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Substrate elasticity dependent colony formation and cardiac differentiation of human induced pluripotent stem cells</article-title>
<source/>Biofabrication
          <year>2018</year>
<volume>11</volume>
<fpage>015005</fpage>
<pub-id pub-id-type="doi">10.1088/1758-5090/aae0a5</pub-id>
<pub-id pub-id-type="pmid">30207295</pub-id>
</element-citation>
</ref>
<ref id="B139-cells-08-00242">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorsey</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Grath</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Multivalent biomaterial platform to control the distinct arterial venous differentiation of pluripotent stem cells</article-title>
<source/>Biomaterials
          <year>2018</year>
<volume>185</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.09.002</pub-id>
<pub-id pub-id-type="pmid">30216805</pub-id>
</element-citation>
</ref>
<ref id="B140-cells-08-00242">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chuah</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.-A.</given-names>
</name>
</person-group>
<article-title>Respective Effects of Gelatin-Coated Polydimethylsiloxane (PDMS) Substrates on Self-renewal and Cardiac Differentiation of Induced Pluripotent Stem Cells (iPSCs)</article-title>
<source/>ACS Biomater. Sci. Eng.
          <year>2018</year>
<volume>4</volume>
<fpage>4321</fpage>
<lpage>4330</lpage>
<pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b00993</pub-id>
</element-citation>
</ref>
<ref id="B141-cells-08-00242">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamaoka</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Effect of stem cell niche elasticity/ECM protein on the self-beating cardiomyocyte differentiation of induced pluripotent stem (iPS) cells at different stages</article-title>
<source/>Acta Biomater.
          <year>2018</year>
<volume>65</volume>
<fpage>44</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/j.actbio.2017.10.032</pub-id>
<pub-id pub-id-type="pmid">29066419</pub-id>
</element-citation>
</ref>
<ref id="B142-cells-08-00242">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goetzke</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Franzen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ostrowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blaeser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rath</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zenke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Does soft really matter? Differentiation of induced pluripotent stem cells into mesenchymal stromal cells is not influenced by soft hydrogels</article-title>
<source/>Biomaterials
          <year>2018</year>
<volume>156</volume>
<fpage>147</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.11.035</pub-id>
<pub-id pub-id-type="pmid">29197223</pub-id>
</element-citation>
</ref>
<ref id="B143-cells-08-00242">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Subbiah</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanotransduction of human pluripotent stem cells cultivated on tunable cell-derived extracellular matrix</article-title>
<source/>Biomaterials
          <year>2018</year>
<volume>150</volume>
<fpage>100</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.10.016</pub-id>
<pub-id pub-id-type="pmid">29035736</pub-id>
</element-citation>
</ref>
<ref id="B144-cells-08-00242">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bandtlow</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Proteoglycans in the developing brain: New conceptual insights for old proteins</article-title>
<source/>Physiol. Rev.
          <year>2000</year>
<volume>80</volume>
<fpage>1267</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.2000.80.4.1267</pub-id>
<pub-id pub-id-type="pmid">11015614</pub-id>
</element-citation>
</ref>
<ref id="B145-cells-08-00242">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galtrey</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Fawcett</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system</article-title>
<source/>Brain Res. Rev.
          <year>2007</year>
<volume>54</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresrev.2006.09.006</pub-id>
<pub-id pub-id-type="pmid">17222456</pub-id>
</element-citation>
</ref>
<ref id="B146-cells-08-00242">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Domowicz</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Proteoglycans in brain development</article-title>
<source/>Glycoconj. J.
          <year>2004</year>
<volume>21</volume>
<fpage>329</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1023/B:GLYC.0000046278.34016.36</pub-id>
<pub-id pub-id-type="pmid">15514481</pub-id>
</element-citation>
</ref>
<ref id="B147-cells-08-00242">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarrazin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lamanna</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Esko</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Heparan sulfate proteoglycans</article-title>
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2011</year>
<volume>3</volume>
<fpage>a004952</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a004952</pub-id>
<pub-id pub-id-type="pmid">21690215</pub-id>
</element-citation>
</ref>
<ref id="B148-cells-08-00242">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oohira</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shuo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tokita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aono</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Neuroglycan C, a brain-specific part-time proteoglycan, with a particular multidomain structure</article-title>
<source/>Glycoconj. J.
          <year>2004</year>
<volume>21</volume>
<fpage>53</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1023/B:GLYC.0000043748.90896.83</pub-id>
<pub-id pub-id-type="pmid">15467399</pub-id>
</element-citation>
</ref>
<ref id="B149-cells-08-00242">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senkov</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Andjus</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Radenovic</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Soriano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dityatev</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neural ECM molecules in synaptic plasticity, learning, and memory</article-title>
<source/>Prog. Brain Res.
          <year>2014</year>
<volume>214</volume>
<fpage>53</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">25410353</pub-id>
</element-citation>
</ref>
<ref id="B150-cells-08-00242">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howell</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Cozart</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Gannon</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Gottschall</surname>
<given-names>P.E.</given-names>
</name>
</person-group>
<article-title>Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2015</year>
<volume>3</volume>
<fpage>54</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-015-0233-z</pub-id>
<pub-id pub-id-type="pmid">26337292</pub-id>
</element-citation>
</ref>
<ref id="B151-cells-08-00242">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Siedlak</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Richey</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cras</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kalaria</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Galloway</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Scardina</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Cordell</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>B.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer’s disease</article-title>
<source/>J. Neurosci.
          <year>1991</year>
<volume>11</volume>
<fpage>3679</fpage>
<lpage>3683</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.11-11-03679.1991</pub-id>
<pub-id pub-id-type="pmid">1941102</pub-id>
</element-citation>
</ref>
<ref id="B152-cells-08-00242">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castillo</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Ngo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wight</surname>
<given-names>T.N.</given-names>
</name>
<name>
<surname>Snow</surname>
<given-names>A.D.</given-names>
</name>
</person-group>
<article-title>Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta fibril formation, and maintains A beta fibril stability</article-title>
<source/>J. Neurochem.
          <year>1997</year>
<volume>69</volume>
<fpage>2452</fpage>
<lpage>2465</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1997.69062452.x</pub-id>
<pub-id pub-id-type="pmid">9375678</pub-id>
</element-citation>
</ref>
<ref id="B153-cells-08-00242">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotman</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Halfter</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.J.</given-names>
</name>
</person-group>
<article-title>Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer’s disease brain</article-title>
<source/>Mol. Cell Neurosci.
          <year>2000</year>
<volume>15</volume>
<fpage>183</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.1999.0816</pub-id>
<pub-id pub-id-type="pmid">10673326</pub-id>
</element-citation>
</ref>
<ref id="B154-cells-08-00242">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandwall</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>O’Callaghan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Lannfelt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Heparan sulfate mediates amyloid-beta internalization and cytotoxicity</article-title>
<source/>Glycobiology
          <year>2010</year>
<volume>20</volume>
<fpage>533</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1093/glycob/cwp205</pub-id>
<pub-id pub-id-type="pmid">20053627</pub-id>
</element-citation>
</ref>
<ref id="B155-cells-08-00242">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Galvis</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zcharia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Metzger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vlodavsky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kisilevsky</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2005</year>
<volume>102</volume>
<fpage>6473</fpage>
<lpage>6477</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0502287102</pub-id>
<pub-id pub-id-type="pmid">15843464</pub-id>
</element-citation>
</ref>
<ref id="B156-cells-08-00242">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leveugle</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Scanameo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fillit</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds</article-title>
<source/>Neuroreport
          <year>1994</year>
<volume>5</volume>
<fpage>1389</fpage>
<lpage>1392</lpage>
<pub-id pub-id-type="pmid">7522615</pub-id>
</element-citation>
</ref>
<ref id="B157-cells-08-00242">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giulian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Haverkamp</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karshin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tom</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kazanskaia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roher</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer’s disease</article-title>
<source/>J. Biol. Chem.
          <year>1998</year>
<volume>273</volume>
<fpage>29719</fpage>
<lpage>29726</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.273.45.29719</pub-id>
<pub-id pub-id-type="pmid">9792685</pub-id>
</element-citation>
</ref>
<ref id="B158-cells-08-00242">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindahl</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Westling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gimenez-Gallego</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Salmivirta</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex</article-title>
<source/>J. Biol. Chem.
          <year>1999</year>
<volume>274</volume>
<fpage>30631</fpage>
<lpage>30635</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.274.43.30631</pub-id>
<pub-id pub-id-type="pmid">10521448</pub-id>
</element-citation>
</ref>
<ref id="B159-cells-08-00242">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kanekiyo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Atagi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>N’Songo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Can</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LRP1 modulates the microglial immune response via regulation of JNK and NF-kappaB signaling pathways</article-title>
<source/>J. Neuroinflamm.
          <year>2016</year>
<volume>13</volume>
<fpage>304</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-016-0772-7</pub-id>
</element-citation>
</ref>
<ref id="B160-cells-08-00242">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamazaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kanekiyo</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>E1965</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18091965</pub-id>
<pub-id pub-id-type="pmid">28902142</pub-id>
</element-citation>
</ref>
<ref id="B161-cells-08-00242">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>DeVos</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Kfoury</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yanamandra</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ouidja</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Brodsky</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Marasa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bagchi</surname>
<given-names>D.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>E3138</fpage>
<lpage>E3147</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1301440110</pub-id>
<pub-id pub-id-type="pmid">23898162</pub-id>
</element-citation>
</ref>
<ref id="B162-cells-08-00242">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Frederickson</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Brunden</surname>
<given-names>K.R.</given-names>
</name>
</person-group>
<article-title>Neuroglial-mediated immunoinflammatory responses in Alzheimer’s disease: Complement activation and therapeutic approaches</article-title>
<source/>Neurobiol. Aging
          <year>1996</year>
<volume>17</volume>
<fpage>781</fpage>
<lpage>787</lpage>
<pub-id pub-id-type="doi">10.1016/0197-4580(96)00103-0</pub-id>
<pub-id pub-id-type="pmid">8892352</pub-id>
</element-citation>
</ref>
<ref id="B163-cells-08-00242">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergamaschini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vergani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Simoni</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: Another target for heparin therapy</article-title>
<source/>Sci. World J.
          <year>2009</year>
<volume>9</volume>
<fpage>891</fpage>
<lpage>908</lpage>
<pub-id pub-id-type="doi">10.1100/tsw.2009.100</pub-id>
<pub-id pub-id-type="pmid">19734963</pub-id>
</element-citation>
</ref>
<ref id="B164-cells-08-00242">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergamaschini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Storini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pizzimenti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Distaso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perego</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Luigi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vergani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Simoni</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer’s disease</article-title>
<source/>J. Neurosci.
          <year>2004</year>
<volume>24</volume>
<fpage>4181</fpage>
<lpage>4186</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0550-04.2004</pub-id>
<pub-id pub-id-type="pmid">15115813</pub-id>
</element-citation>
</ref>
<ref id="B165-cells-08-00242">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scholefield</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Wayne</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Amour</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McDowell</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer’s beta-secretase</article-title>
<source/>J. Cell Biol.
          <year>2003</year>
<volume>163</volume>
<fpage>97</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200303059</pub-id>
<pub-id pub-id-type="pmid">14530380</pub-id>
</element-citation>
</ref>
<ref id="B166-cells-08-00242">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bejoy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>Q.X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Neuroprotective Activities of Heparin, Heparinase III, and Hyaluronic Acid on the Aβ42-treated Forebrain Spheroids Derived from Human Stem Cells</article-title>
<source/>ACS Biomater. Sci. Eng.
          <year>2018</year>
<volume>4</volume>
<fpage>2922</fpage>
<lpage>2933</lpage>
<pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b00021</pub-id>
<pub-id pub-id-type="pmid">30533518</pub-id>
</element-citation>
</ref>
<ref id="B167-cells-08-00242">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sorrells</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Paredes</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Cebrian-Silla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sandoval</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Auguste</surname>
<given-names>K.I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults</article-title>
<source/>Nature
          <year>2018</year>
<volume>555</volume>
<fpage>377</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="doi">10.1038/nature25975</pub-id>
<pub-id pub-id-type="pmid">29513649</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="cells-08-00242-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>A possible pathology of Alzheimer’s disease (AD). It is postulated that AD may be caused by the deposition of Aβ and tau hyperphosphorylation-derived neurofibrillary tangles (NFTs), both of which could activate the caspase-associated apoptosis. In AD brain the monomeric Aβ peptides aggregate to form toxic Aβ oligomers and further generate the insoluble fibrils, which ultimately form the plaques. The toxic Aβ species could trigger an inflammatory response and increase the level of ROS, which may cause neuron death. On the other hand, toxic Aβ species may be transferred into cells and trigger the apoptosis of neurons. NFTs could either cause neuronal cell death or trigger apoptosis of neurons. Aβ may interplay with tau-derived NFTs formation, while critical questions about Aβ-induced tau pathology in AD are still unanswered. ECM: extracellular matrix; APP: amyloid precursor protein; ROS: reactive oxygen species; SAT3: signal transducer and activator of transcription 3; JNK: c-Jun N-terminal kinase; GSK-3β: glycogen synthase kinase-3β.</p>
</caption>
<graphic xlink:href="cells-08-00242-g001"></graphic>
</fig>
<fig id="cells-08-00242-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Schematic illustration of the process flow of using hiPSCs for AD studies. The neuronal cells derived from iPSCs cells of AD patients can be used for AD pathological analysis and various therapeutic interventions. AD: Alzheimer’s disease.</p>
</caption>
<graphic xlink:href="cells-08-00242-g002"></graphic>
</fig>
<fig id="cells-08-00242-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Regional specification in neural differentiation of pluripotent stem cells (PSCs) mimicking in vivo regional patterning, and the use of the derived forebrain organoids for AD modeling. The regional patterning of brain organoids was achieved by cell signaling modulators and the corresponding organoids generated were used for disease modeling. DA: dopaminergic; FGF: fibroblast growth factor; RA: retinoic acid; SHH: Sonic Hedgehog; BDNF: Brain-derived neurotropic growth factor; SDF: Stromal cell-derived factor. Adapted and revised from [<xref ref-type="bibr" rid="B81-cells-08-00242">81</xref>].</p>
</caption>
<graphic xlink:href="cells-08-00242-g003"></graphic>
</fig>
<fig id="cells-08-00242-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Organoid formation from human pluripotent stem cells. (<bold>A</bold>) Organoids can be generated from human pluripotent stem cells through the embryonic body (EB)-based procedure with the help of exogenous factors, such as extracellular matrix (ECM). Organoids form 3D ordered structures to mimic the in vivo situation of tissues or cells. (<bold>B</bold>) Organoids form based on the self-organization and self-assembly of stem cells.</p>
</caption>
<graphic xlink:href="cells-08-00242-g004"></graphic>
</fig>
<fig id="cells-08-00242-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>A hypothetical model of heparan sulfate proteoglycan (HSPG) (e.g., agrin/perlecan) involvement in Aβ pathogenesis. ECM: extracellular matrix.</p>
</caption>
<graphic xlink:href="cells-08-00242-g005"></graphic>
</fig>
<fig id="cells-08-00242-f006" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>Possible protective actions of heparin in Alzheimer’s disease (AD) pathology. Heparin-based protection can be realized by: (1) reduction of Aβ generation by an action on amyloid precursor protein (APP); (2) prevention of Aβ aggregation/deposition in senile plaques; (3) reduction of the inflammatory response (complement, kinin system); (4) binding to homotetrameric Cu<sup>2+</sup> and Zn<sup>2+</sup> containing glycoprotein, and regulating the activity of these metals which reduce accumulation of Aβ peptides. (Red line indicates the actions of heparin on Aβ).</p>
</caption>
<graphic xlink:href="cells-08-00242-g006"></graphic>
</fig>
<table-wrap id="cells-08-00242-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">cells-08-00242-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Selected studies of hPSC-based models for Alzheimer’s disease.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cell Line</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Neural Types</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">AD Phenotypes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Chemicals Induced AD-Phenotypes Using hPSCs</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESC-derived neurons treated with Aβ42 oligomers</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D neurospheres and 2D, basal forebrain cholinergic neurons expressing ChAT and β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Aβ oligomers suppressed the number of functional neurons</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wicklund et al., 2010 [<xref ref-type="bibr" rid="B31-cells-08-00242">31</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HiPSC-derived neurons treated with β-secretase (BSI) and γ-secretase inhibitor (GSI) and NSAID</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, forebrain neurons expressing FOXG1 and TBR1 (62%), CTIP2 (12%), Cux1 (83%) SATB (46%) at day 52</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Differentiated neuronal cells expressed Aβ40 and Aβ42. BSI, GSI, and NSAID partially or fully blocked Aβ production in the hiPSCs-derived neuronal cells</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yahata et al., 2011 [<xref ref-type="bibr" rid="B32-cells-08-00242">32</xref>] </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESC and hiPSC-derived neurons treated with Aβ42 oligomers</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical glutamatergic neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Aβ oligomers yielded cell culture age-dependent binding of Aβ and cell death in the glutamatergic populations</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vazin et al., 2014 [<xref ref-type="bibr" rid="B25-cells-08-00242">25</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HiPSC-derived neurons treated with Aβ1-42 oligomers</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D neurospheres, cortical glutamatergic neurons, and motor neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Aβ oligomers caused less cell viability, more caspase expression and higher ROS levels on cortical excitatory neurons population. GSK-3β inhibitor may attenuate Aβ-induced cytotoxicity</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yan et al., 2016 [<xref ref-type="bibr" rid="B26-cells-08-00242">26</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HiPSC-derived neurons induced by Aβ42 inducer (Aftin5)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D cortical organoids, neurons expressing NeuN, NCAM, MAP2, and CTIP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased secretion of Aβ42 and the Aβ42/40 ratio</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pavoni et al., 2018 [<xref ref-type="bibr" rid="B24-cells-08-00242">24</xref>]</td>
</tr>
<tr>
<td align="center" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Overexpression of AD-related gene in hPSCs using genetic modification</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PSEN1 L166P mutant hPSC-derived neurons treated with γ-secretase inhibitor (DAPT) and NSAID</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, hPSC-derived neural stem cells (NSCs) expressing Nestin and β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DAPT reduced secretion of both Aβ42 and Aβ40. NSAID reduced secretion of Aβ42. PSEN1 1L166P mutation resulted in elevated Aβ42/40 ratio.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Koch et al., 2012 [<xref ref-type="bibr" rid="B27-cells-08-00242">27</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PSEN1 (∆E9) mutant hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, hPSC-derived neural progenitor cells (NPCs) expressing Nestin and tau</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The PS1 ∆E9 mutation increases the Aβ42/Aβ40 ratio in human neurons by decreasing Aβ40</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Woodruff et al., 2013 [<xref ref-type="bibr" rid="B28-cells-08-00242">28</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESC-derived neurons model tau pathology</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neurons expressing Nestin, DACH1, SOX2, β-tubulin III, and tau</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">P-tau impaired the transport of mitochondria and led to axonal degeneration and cell death</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mertens et al., 2013 [<xref ref-type="bibr" rid="B33-cells-08-00242">33</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HPSC-derived neurons co-cultured with ApoE secreted glia</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, human neurons generated by forced expression of neurogenin-2 (Ngn2), expressing MAP2 and NeuN</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ApoE secreted by glia stimulates neuronal Aβ40 and Aβ42 production with an ApoE4 &gt; ApoE3 &gt; ApoE2 potency rank order</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Huang et al., 2017 [<xref ref-type="bibr" rid="B29-cells-08-00242">29</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human NPCs and hiPSC-derived cells overexpressed APP (K670N/M671L and V717I) mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D microfluidic platform, tri-culture of neurons, astrocytes, and microglia</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased Aβ aggregation and p-tau formation, induced microglia recruitment and axonal cleavage. Increased chemokines and cytokines.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Park et al., 2018 [<xref ref-type="bibr" rid="B30-cells-08-00242">30</xref>]</td>
</tr>
<tr>
<td align="center" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>AD patient-derived iPSCs</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1/2 mutations </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neurons expressing β-tubulin III (about 80%) and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Change in APP processing; increased Aβ42 secretion; responding to γ-secretase inhibitors and modulators.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yagi et al., 2011 [<xref ref-type="bibr" rid="B34-cells-08-00242">34</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs from a patient with Down’s syndrome (Trisomy 21 defect)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical glutamatergic neurons expressing TBR1, CTIP2, SATB and β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased Aβ peptide production, Intracellular and extracellular Aβ42 aggregates. Decreased Aβ40/Aβ42 with γ-secretase inhibitors. Tau hyper-phosphorylation in cell bodies and dendrites. Neuronal cell death.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Shi et al., 2012 [<xref ref-type="bibr" rid="B35-cells-08-00242">35</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP gene duplications and SAD-hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, FACS-purified neurons expressing β-tubulin III (&gt;90%) and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neurons from AD patients had higher levels of Aβ40, p-tau, and active glycogen synthase kinase-3β (aGSK-3β). β-secretase inhibitors, not γ-secretase inhibitors, reduced p-tau and aGSK-3b.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Israel et al., 2012 [<xref ref-type="bibr" rid="B36-cells-08-00242">36</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP mutations and SAD-hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical neurons expressing β-tubulin III, MAP2, TBR1 and SATB2, and astrocytes expressing GFAP</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intracellular Aβ oligomer formation; reduced extracellular Aβ peptides.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kondo et al., 2013 [<xref ref-type="bibr" rid="B37-cells-08-00242">37</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP or PSEN1 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neural stem cells (NSCs) expressing Nestin SOX2, ZO1, β-tubulin III, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the Aβ42/Aβ40 ratio compared to healthy control. With high concentrations of γ-secretase inhibitors (NSAID-based GSMs drugs), Aβ42/Aβ40 ratio was decreased.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mertens et al., 2013 [<xref ref-type="bibr" rid="B38-cells-08-00242">38</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, NPCs expressing β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the Aβ42/Aβ40 ratio.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sproul et al., 2014 [<xref ref-type="bibr" rid="B39-cells-08-00242">39</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (A246E) mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D EB-based, neurons expressing Nestin, PAX6, FOXG1, TBR1, STAB2, β-tubulin III, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the Aβ42/Aβ40 ratio, increased expression of FOXG1, mGluR1, and SYT1.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mahairaki et al., 2014 [<xref ref-type="bibr" rid="B40-cells-08-00242">40</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 and AG mutations and SAD-hiPSCs with APOE3/E4 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Basal forebrain cholinergic neurons expressing MAP2, ChAT, and VaChT</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elevated Aβ42. With γ-secretase inhibitors, Aβ40 was increased and calcium transient was increased.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Duan et al., 2014 [<xref ref-type="bibr" rid="B41-cells-08-00242">41</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D EB-based, forebrain neurons expressing MAP2, tau, β-tubulin III, Cux1, TBR1, vGlut1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased Aβ42: Aβ40; Decreased APPsα: APPsβ, γ-secretase inhibitor blocked APPs, β cleavage. Increased total tau and p-tau (Ser262) d100. Aβ antibodies blocked, increased total tau.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Muratore et al., 2014 [<xref ref-type="bibr" rid="B42-cells-08-00242">42</xref>] </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (A246E, H163R or M146L) mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neurons expressing Nestin, PAX6 and SOX1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the Aβ42/Aβ40 ratio compared to healthy control. Reduced Aβ42 and Aβ38 by γ-secretase inhibitor-GSM4.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Liu et al., 2014 [<xref ref-type="bibr" rid="B43-cells-08-00242">43</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D EB based, neurons expressing β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the Aβ42 secretion level. Elevated acid sphingomyelinase (ASM) levels. ASM levels restored by ASM siRNA treatment.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lee et al., 2014 [<xref ref-type="bibr" rid="B44-cells-08-00242">44</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs with SOR1 variants</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, FACS-purified neurons expressing Nestin and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered induction of SORL1 expression; altered Aβ peptide production.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Young et al., 2015 [<xref ref-type="bibr" rid="B45-cells-08-00242">45</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 or APP mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical excitatory neurons expressing tau</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased the Aβ42 secretion level.<break></break>Increased intracellular tau and phosphorylated tau levels.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Moore et al., 2015 [<xref ref-type="bibr" rid="B46-cells-08-00242">46</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs with APP mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neurons expressing Nestin, PAX6 and β-tubulin III </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased phosphor-tau (p-tau) and active glycogen synthase kinase-3β (aGSK-3β).Reduced p-tau by γ-secretase inhibitor.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hossini et al., 2015 [<xref ref-type="bibr" rid="B47-cells-08-00242">47</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (A246E) mutations and SAD-hiPSC mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neurons expressing Nestin, SOX2, MAP2, and β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased Aβ42 for FAD-hiPSCs-derived neurons.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Armijo et al., 2016 [<xref ref-type="bibr" rid="B48-cells-08-00242">48</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (P117R)/APOE3/3 mutations and SAD-hiPSCs with APOE3/E4 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D neurospheres, neural cells expressing GFAP, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced neurites length and neuronal viability. Elevated levels of nitrite and apoptosis. Hyper-excitable Ca<sup>+</sup> signaling phenotype. Protected neurites and cell viability by treatment of apigenin.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Balez et al., 2016 [<xref ref-type="bibr" rid="B49-cells-08-00242">49</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP (V717I) mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D EB based, forebrain neurons expressing GABA, PVB, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elevated levels of Aβ and sAPPα.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Liao et al., 2016 [<xref ref-type="bibr" rid="B50-cells-08-00242">50</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D neuro-spheroid, cortical neurons expressing PAX6, MAP2, NeuN and β-tubulin III</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D spheroids recapitulated both amyloid β and tau pathology. Reduced Aβ42 and Aβ40 production both in 2D and 3D neurons with BACE1 or γ-secretase inhibitors.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lee et al., 2016 [<xref ref-type="bibr" rid="B51-cells-08-00242">51</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-human iPSCs with APP or PS1 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D brain organoids, neuronal cells expressing SOX2, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D organoids recapitulated amyloid β, tau pathology, and endosome abnormalities. Reduced amyloid and tau pathology with β-and γ-secretase inhibitors.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Raja et al., 2016 [<xref ref-type="bibr" rid="B52-cells-08-00242">52</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (M146L) mutations and SAD-hiPSCs with APOE4 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D differentiation; cortical neurons and astrocytes</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced morphological heterogeneity in astrocytes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Jones et al., 2017 [<xref ref-type="bibr" rid="B53-cells-08-00242">53</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP (V717I) mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D EB-based differentiation, caudal neurons expressing HOXB4 and rostral neurons expressing TBR1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced the Aβ42/Aβ40 ratio but increased the Aβ38/Aβ42 ratio for caudal neurons. Higher levels of total and phosphor-tau for rostral neuronal fate.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Muratore et al., 2017 [<xref ref-type="bibr" rid="B54-cells-08-00242">54</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (M146L, G384A, H163R or A246E), APP (V717I) mutations and SAD-hiPSCs with APOE4 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, human cortical neurons (iN cells) generated by force expression of neurogenin-2 (Ngn2), iN cells expressing SATB2, MAP2, vGlut1, and TBR2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">iPSC-based screening of pharmaceutical compounds for Aβ phenotypes; anti-Aβ cocktail decreased toxic Aβ levels in neurons derived from patients’ cells. A combination of existing drugs synergistically improved Aβ phenotypes of AD.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kondo et al., 2017 [<xref ref-type="bibr" rid="B55-cells-08-00242">55</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 mutations and SAD-hiPSCs with unknown mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cholinergic neurons (VAChT), dopaminergic neurons (TH), GABAergic neurons (GAD2/GAD1), and glutamatergic neurons (vGlut1/2)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased levels of extracellular Aβ40 and Aβ42 for FAD and SAD samples. Increased the Aβ42/Aβ40 ratio for FAD sample. Increased levels of p-tau and GSK3β.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ochalek et al., 2017 [<xref ref-type="bibr" rid="B56-cells-08-00242">56</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (∆E9) mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D EB-based differentiation, astrocytes expressing GFAP and S100β</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AD astrocytes increased Aβ42 production, altered cytokine release, dysregulated Ca<sup>2+</sup> homeostasis, increased oxidative stress and reduced lactate secretion.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Oksanen et al., 2017 [<xref ref-type="bibr" rid="B57-cells-08-00242">57</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSC with PSEN1 and APP duplication or hiPSCs from Down’s syndrome (Trisomy 21)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical neurons expressing TBR1, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Synaptic dysfunction (long-term potentiation) caused by PSEN1 and APP duplication secretomes was mediated by Aβ peptides, whereas trisomy 21 neuronal secretomes induced dysfunction through extracellular tau.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hu et al., 2018 [<xref ref-type="bibr" rid="B58-cells-08-00242">58</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with PSEN1 (M146V) mutation</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D cortical organoids, neurons expressing TBR1, SATB2, BRN2, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D organoids recapitulated Aβ, tau pathology, and neuronal cell death. Reduced amyloid β with DAPT, heparin and heparinase.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yan et al., 2018 [<xref ref-type="bibr" rid="B59-cells-08-00242">59</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSC with PSEN1 (A246E) or hiPSCs from Down’s syndrome (Trisomy 21)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D cortical organoids, neurons expressing NeuN, SATB2, TBR1, and MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Accumulation of Aβ and tau aggregates and induced cellular apoptosis AD organoids.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gonzalez et al., 2018 [<xref ref-type="bibr" rid="B60-cells-08-00242">60</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs from APOE4/E3 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D organoids,<break></break>neurons, astrocytes, and microglia-like cells</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">APOE4 organoids displayed increased Aβ aggregation and hyperphosphorylation of tau.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lin et al., 2018 [<xref ref-type="bibr" rid="B61-cells-08-00242">61</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs from unknown mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3D neuro-spheroid, neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AD organoids neuronal dysfunction was similar to AD brain tissue by mass spectrometry-based proteomics analysis.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chen et al., 2018 [<xref ref-type="bibr" rid="B62-cells-08-00242">62</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs from APOE4/E3 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, neuronal cells expressing MAP2</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Showed aberrant mitochondrial function.<break></break>Increased levels of ROS and DNA damage. Increased levels of oxidative phosphorylation chain complexes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Birnbaum et al., 2018 [<xref ref-type="bibr" rid="B63-cells-08-00242">63</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs and SAD-hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, FACS-purified neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reduced tau phosphorylation by retromer stabilization.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Young et al., 2018 [<xref ref-type="bibr" rid="B64-cells-08-00242">64</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HiPSCs from a Down’s syndrome patient by controlling APP gene copy number</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Higher APP gene dosage increased Aβ production, altered the Aβ42/Aβ40 ratio and caused deposition of the pyroglutamate (E3)-containing amyloid aggregates.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ovchinnikov et al., 2018 [<xref ref-type="bibr" rid="B65-cells-08-00242">65</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SAD-hiPSCs from APOE4/4 or APOE3/3 mutations</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, cortical neurons and GABAergic neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">APOE4 increased Aβ production in human neurons, APOE4-expressing neurons had higher levels of tau phosphorylation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wang et al., 2018 [<xref ref-type="bibr" rid="B66-cells-08-00242">66</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FAD-hiPSCs with APP duplication mutants</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2D, FACS-purified neurons </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuronal cholesteryl esters (CE) regulated the proteasome-dependent degradation of p-tau, CE-mediated Aβ secretion by a cholesterol-binding down in APP, A CYP46A1-CE-tau axis was identified as an early pathway.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">van der Kant et al., 2019 [<xref ref-type="bibr" rid="B67-cells-08-00242">67</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Note: PSCs, pluripotent stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; AD, Alzheimer’s disease; Aβ, β-amyloid peptide; 2D, two-dimensional; 3D, three-dimensional; BSI/BACE1, β-secretase inhibitor; GSI, γ-secretase inhibitor; NSAID, nonsteroidal anti-inflammatory drug; ROS, reactive oxygen species; GSK-3β, glycogen synthase kinase 3 beta; NSCs, neural stem cells, NPCs, neural progenitor cells; PSEN1/2, presenlin1/2; APP, amyloid precursor protein; FAD, familial AD; SAD, sporadic AD; EB, embryoid body; FACS, fluorescence-activated cell sorting; ChAT: Choline Acetyltransferase. Other Useful studies: Hu et al., 2015 Cell Stem Cell [<xref ref-type="bibr" rid="B68-cells-08-00242">68</xref>], Human chemical-induced neuronal cells (hciNs) from FAD patient fibroblasts with APP (V717I) or PSEN1 (I167del or A434T or S169del) mutations, increased extracellular Aβ42 level and the Aβ42/Aβ40 ratio. Espuny-Camacho et al., 2017 Neuron [<xref ref-type="bibr" rid="B69-cells-08-00242">69</xref>], Chimeric model of AD generated using hPSCs-derived neurons (hPSC-neurons grafted into AD mice), major degeneration and loss of human neurons in chimeric AD mice, absence of tangle pathology in degenerating human neurons in vivo. Wang et al., 2017 Stem Cell Reports [<xref ref-type="bibr" rid="B70-cells-08-00242">70</xref>], Neurogenin 2 (NGN2)-induced glumatergic neurons (iN cells) from hiPSCs, iN cells are used to identify tau-lowering compounds in LOPAC (Library of Pharmacologically Active Compounds), and identified adrenergic receptors agonists as a class of compounds that reduce endogenous human tau.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="cells-08-00242-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">cells-08-00242-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Effects of matrix modulus on pluripotent stem cell fate decisions.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cell Source</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Range of Modulus and Substrates</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Effect on Morphology, Proliferation, and Differentiation</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neural progenitor cells</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.1 kPa–10 kPa; PA gels based vmIPNs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft gel (100–500 Pa) favored neurons, harder gel (1–10 kPa) promoted glial cells.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Saha et al., 2009 [<xref ref-type="bibr" rid="B111-cells-08-00242">111</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neural progenitor cells</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1–20 kPa; MAC substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&lt;1 kPa favored neuronal differentiation; &lt;3.5 kPa supported astrocyte, &gt;7kPa favored oligodendrocyte.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Leipzig et al., 2009 [<xref ref-type="bibr" rid="B112-cells-08-00242">112</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">41–2700 kPa; collagen coated PDMS surface</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increasing substrate stiffness from 41–2700 kPa promoted cell spreading, proliferation, mesendodermal and osteogenic differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Evans et al., 2009 [<xref ref-type="bibr" rid="B122-cells-08-00242">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rat neural stem cells</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">180–20,000 Pa; 3D alginate hydrogel scaffolds</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The rate of proliferation of neural stem cells decreased with an increase in the modulus of the hydrogels. Lower stiffness enhanced neural differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Banerjee et al., 2009 [<xref ref-type="bibr" rid="B123-cells-08-00242">123</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.6 kPa; PA gel substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft substrate supported self-renewal</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Chowdhury et al., 2010 [<xref ref-type="bibr" rid="B124-cells-08-00242">124</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs and iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.7–10 kPa; GAG-binding hydrogel</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The stiff (10 kPa) hydrogel maintained cell proliferation and pluripotency.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Musah et al., 2012 [<xref ref-type="bibr" rid="B125-cells-08-00242">125</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.05–7 MPa, 3D PLLA, PLGA, PCL or PEGDA scaffold coated with matrigel</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">50 to 100 kPa supported ectoderm differentiation; 100 to 1000 kPa supported endoderm differentiation; 1.5 to 6 MPa supported mesoderm differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Zoldan et al., 2011 [<xref ref-type="bibr" rid="B126-cells-08-00242">126</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs and iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.1–75 kPa; matrigel-coated PA gels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft matrix (0.1 kPa) promoted early neural differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Keung et al., 2012 [<xref ref-type="bibr" rid="B119-cells-08-00242">119</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1 kPa, 10 kPa, 3 GPa;<break></break>PDMS substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rigid matrix promoted cardiac differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Arshi et al., 2013 [<xref ref-type="bibr" rid="B127-cells-08-00242">127</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0–1.5 kPa, 3D collagen-I, Matrigel, or HA hydrogel</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&lt;0.3 kPa less neurite outgrowth and supported glial cell; 0.5 to 1 kPa more neurite outgrowth and supported neurons.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kothapalli et al., 2013 [<xref ref-type="bibr" rid="B113-cells-08-00242">113</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.078–1.167 MPa; PDMS substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased stiffness upregulated mesodermal differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Eroshenko et al., 2013 [<xref ref-type="bibr" rid="B128-cells-08-00242">128</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.3 kPa, 2.1 kPa, 3.5 kPa; HA hydrogel</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stiffness of 1.2 kPa was the best to support pancreatic β-cell differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Narayanan et al., 2014 [<xref ref-type="bibr" rid="B129-cells-08-00242">129</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4–80 kPa; PA hydrogels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stiffness of 50 kPa was the best for cardiomyocyte differentiation. Stiffness impacted the initial differentiation of hESCs to mesendoderm, while it did not impact differentiation of cardiac progenitor cells to cardiomyocytes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hazeltine et al., 2014 [<xref ref-type="bibr" rid="B130-cells-08-00242">130</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19–193 kPa; 3D PCL, PET, PEKK or PCU electrospun fibers </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">The substrate stiffness was inversely related to the sphericity of hiPSC colonies.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Maldonado et al., 2015 [<xref ref-type="bibr" rid="B131-cells-08-00242">131</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6 kPa, 10 kPa, 35 kPa; Matrigel micropatterns</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">High stiffness (35 kPa) induced myofibril defects of hPSC-derived cardiomyocytes and decreased mechanical output.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ribeiro et al., 2015 [<xref ref-type="bibr" rid="B132-cells-08-00242">132</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">hPSC-derived hepatocytes (hPSC-Heps) </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20, 45, 140 kPa; collagen-coated PA hydrogels substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">On softer substrates, the hPSC-Heps formed compact colonies while on stiffer substrates they formed a diffuse monolayer. Albumin production correlated inversely with stiffness.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mittal et al., 2016 [<xref ref-type="bibr" rid="B133-cells-08-00242">133</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rat cortical neurons (RCN)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5 kPa (soft), PA gels;<break></break>500 kPa (stiff), PDMS substrates;</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft substrates enhanced cortical neurons migration. Stiff substrates increased synaptic activity.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Lantoine et al., 2016 [<xref ref-type="bibr" rid="B114-cells-08-00242">114</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse ESCs and iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">300–1200 Pa; 3D PEG hydrogels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stiffness and other biophysical effectors promoted somatic-cell reprogramming and iPSC generation; lower modulus (300–600 Pa) showed higher reprogramming efficiency.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Caiazzo et al., 2016 [<xref ref-type="bibr" rid="B134-cells-08-00242">134</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">400 Pa, 60 kPa; PA hydrogels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">On stiff substrates, β-catenin degradation inhibits mesodermal differentiation of human ESCs.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Przybyla et al., 2016 [<xref ref-type="bibr" rid="B135-cells-08-00242">135</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1–100 kPa; barium alginate capsules</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stiffness of 4–7 kPa supported cell proliferation and higher stiffness suppressed cell growth. Increased stiffness promoted endoderm differentiation, while suppressed pancreatic induction. About 3.9 kPa was the best for pancreatic differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Richardson et al., 2016 [<xref ref-type="bibr" rid="B136-cells-08-00242">136</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse intestinal stem cells (ISC)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">300 Pa, 700 Pa, 1.3 kPa, 1.7 kPa; PEG hydrogels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Higher stiffness enhanced ISC expansion. Lower stiffness supported ISC differentiation and organoid formation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gjorevski et al., 2016 [<xref ref-type="bibr" rid="B137-cells-08-00242">137</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse neural progenitor cells (NPC)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.5–50 kPa; 3D elastin-like protein hydrogels</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">In stiffness from 0.5 to 50 kPa, NPC stemness maintenance did not correlate with initial hydrogel stiffness.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Madl et al., 2017 [<xref ref-type="bibr" rid="B115-cells-08-00242">115</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse ESCs and hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10–100 kPa; 3D PU scaffolds</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Scaffolds with proper stiffness, Poisson’s ratio and pore structure enhanced neural differentiation of PSCs.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Yan et al., 2017 [<xref ref-type="bibr" rid="B108-cells-08-00242">108</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3–168 kPa; PDMS substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Elasticity of substrates significantly affected cell colony formation. Intermediate substrate elasticity of about 9 kPa is preferable to reach an EB-like aggregation and optimal for cardiac differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wang et al., 2018 [<xref ref-type="bibr" rid="B138-cells-08-00242">138</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.4 kPa, 64 kPa, 144 kPa; PEGDA or PEG hydrogel substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft hydrogel (3.4 kPa) showed strong cell attachment and a growth pattern similar to 2D surface. Stiff hydrogel (144 kPa) supported a 3D aggregation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dorsey et al., 2018 [<xref ref-type="bibr" rid="B139-cells-08-00242">139</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0–2.4 MPa; PDMS substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stiffer substrate supported pluripotency of iPSCs. Softer substrate promoted cardiac differentiation.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fu et al., 2018 [<xref ref-type="bibr" rid="B140-cells-08-00242">140</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neural crest stem cells (NCSCs) from hiPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1kPa, 15 kPa, 1 GPa; PA gel substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&gt;50 kPa promoted smooth muscle cells from NCSCs, &lt;15 kPa promoted glial cells from NCSCs.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Zhu et al., 2018 [<xref ref-type="bibr" rid="B116-cells-08-00242">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mouse hippocampal neurons</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.13 kPa, 22.1 kPa; PDMS substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Stiff substrate enhanced voltage-gated Ca<sup>2+</sup> channel currents in neurons.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wen et al., 2018 [<xref ref-type="bibr" rid="B117-cells-08-00242">117</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neural crest stem cells (NCSCs) derived from hESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.3 kPa, 1.7 MPa, 1 GPa; PDMS substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft substrate increased differentiation of ectodermal mesenchymal stem cells (MSCs) from NCSCs via CD44 mediated PDGFR signaling.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Srinivasan et al., 2018 [<xref ref-type="bibr" rid="B118-cells-08-00242">118</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">iPSCs and neonatal rat cardiomyocytes</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9, 20, 180 kPa; PA gel substrates</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cardiac differentiation preferred rigid substrates, and beating behavior preferred soft substrate.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hirata et al., 2018 [<xref ref-type="bibr" rid="B141-cells-08-00242">141</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human iPSCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">About 24 Pa, fibrin-based gel substrates (human platelet lysate gel); &gt;1 GPa, tissue culture plastics</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft substrates did not impact on differentiation of iPSCs into MSCs.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Goetzke et al., 2018 [<xref ref-type="bibr" rid="B142-cells-08-00242">142</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human ESCs</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">118 ± 51 Pa, 800 ± 180 Pa, 5600 ± 1100 Pa, and 8900 ± 1500 Pa; decellularized fibroblast-derived matrices crosslinked by genipin</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Soft matrix supported cell migration and induced EMT of hPSC. Stiff matrix supported cell pluripotency and suppressed EMT of hPSCs.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kim et al., 2018 [<xref ref-type="bibr" rid="B143-cells-08-00242">143</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Note: PA, polyacrylamide; vmIPNs, variable moduli interpenetrating polymer networks; MAC, methacrylamide chitosan; PDMS, polydimethylsiloxane; HA, hyaluronic acid; PLLA, poly-L-lactide acid; PLGA: poly(lactic co-glycolic acid); PCL, polycaprolactone; PEGDA, polyethylene glycol diacrylate; PET, polyrethylene terephthalate; PEKK, poly(etherketoneketone); PCU, polycarbonate-urethane; GAG, glycosaminoglycan; PEG, polyethylene glycol; PU, polyurethane; PDGFR, platelet-derived growth factor receptor beta (PDGFRβ) signaling; EMT, epithelial-mesenchymal-transition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>